Abstract
Migraine is a common, little understood, and debilitating disease. It is much more prominent in women than in men (~2/3 are women) but the reasons for female preponderance are not clear. Migraineurs frequently experience severe comorbidities, such as allergies, depression, irritable bowel syndrome, and others; many of the comorbidities are more common in females. Current treatments for migraine are not gender specific, and rarely are migraine and its comorbidities considered and treated by the same specialist. Thus, migraine treatments represent a huge unmet medical need, which will only be addressed with greater understanding of its underlying pathophysiology. We discuss the current knowledge about sex differences in migraine and its comorbidities, and focus on the potential role of mast cells (MCs) in both. Sex-based differences in pain recognition and drug responses, fluid balance, and the blood–brain barrier are recognized but their impact on migraine is not well studied. Furthermore, MCs are well recognized for their prominent role in allergies but much less is known about their contributions to pain pathways in general and migraine specifically. MC-neuron bidirectional communication uniquely positions these cells as potential initiators and/or perpetuators of pain. MCs can secrete nociceptor sensitizing and activating agents, such as serotonin, prostaglandins, histamine, and proteolytic enzymes that can also activate the pain-mediating transient receptor potential vanilloid channels. MCs express receptors for both estrogen and progesterone that induce degranulation upon binding. Furthermore, environmental estrogens, such as Bisphenol A, activate MCs in preclinical models but their impact on pain pathways or migraine is understudied. We hope that this discussion will encourage scientists and physicians alike to bridge the knowledge gaps linking sex, MCs, and migraine to develop better, more comprehensive treatments for migraine patients.
Introduction
Migraine is the most common neurological disorder, affecting 18% of females and 6% of males, with prevalence peaking at age 30–40 years. Since migraine triggers include stress, alcohol, menstrual cycling, missing meals, or sleep, it is not surprising that migraine prevalence peaks when other significant personal, family, professional, and financial responsibilities are also pressing. The female preponderance of migraine suggests that factors increasing female vulnerability and/or protecting males deserve greater consideration as contributors to migraine pathology.
The incapacitating features of migraine include episodic severe headache, accompanied by pain or severe discomfort in response to normal light, sounds, smells, touch, and often associated with nausea, vomiting, or vertigo. Symptoms are typically worse on movement and may last from 4 to 72 h, though a substantial number of sufferers (three million in the US) develop chronic daily headache (CDH). Only about 25% of migraineurs have a warning pre-headache aura, usually a short-lived, migrating visual hallucination. Common migraine comorbidities affect multiple organ systems in addition to the CNS (1). These include Raynaud’s phenomenon, hypertension, interstitial cystitis/bladder pain syndrome (IC/BPS), allergy and asthma, irritable bowel syndrome (IBS), osteo- and rheumatoid arthritis, anxiety, tremor, and depression (2–7). The molecular underpinnings common to and connecting these disorders are not known, but may include shared genetic risk factors (1, 8), regulation of brain cations (9, 10), or common receptor signaling events that activate pain (11), inflammation (12), or oxidative (13) pathways.
Treatment of migraine is multimodal, including lifestyle modifications, relaxation, yoga, physical therapy, massage, acupuncture, biofeedback, and cognitive-behavioral therapy, as well as prescription medications and over-the-counter supplements. Medications are directed at prophylaxis or rescue (14–17). A recent review describes rescue and prevention of menstrual migraine (18).
Quantification of Pain
One barrier to effectively dealing with migraine, common to all chronic pain states, is quantifying the severity of “real” pain. Subjective metrics are difficult to translate across studies and objective measures fail to capture the true significance of pain. The best clinical practices require intensive patient–doctor dialog and individual patient education, also not easily translatable across studies. Useful clinical tools include FACES (developed for children), numeric (0–10), visual analog, and verbal pain scales. Descriptive terms (hot/cold, dull/sharp, and superficial/deep) can help classify pain (somatic, visceral, or neuropathic), and locations provide sensory discrimination often useful for diagnosis and treatment. There is a real unmet need for objective measures of pain. For example, electromyography (EMG) is used to measure ocular photic discomfort and facial grimace scores (an observation-based version of the FACES pain scale) (19, 20) [Kardon and Poolman, University of Iowa, VA Center of Excellence Iowa City, personal communication]. Brain mapping can identify brain regions activated in specific pain conditions, including migraine (21–24) and photophobia from corneal damage (25), but resolution is poor and not standardized for clinical use (26). The posterior insular-opercular, prefrontal cortex, and anterior cingulate cortex were identified as regions of interest for migraine in a meta-analysis of 22 migraine patients and controls using voxel-based morphometry. Notably, more women than men showed decreased gray matter in the dorsolateral prefrontal cortex (27). Ideal objective pain measures must be validated against clinical pain scales and must also reflect affective and motivational aspects of pain.
The Pathophysiology of Migraine
In spite of the commonness of migraine, its burden on society, and WHO recognition of migraine in the world’s top 20 most disabling conditions (26), its pathophysiology is incompletely understood (Figure 1) (28). We do not know if a common pathway, component, or event is disrupted in migraineurs generally vs. in non-migraineurs, or whether migraine is really several diseases. Candidate mechanisms include cortical spreading depression (CSD) (29–31); dysregulation of neuropeptides (32); sterile meningeal neuroinflammation (33, 34) with triggering of dural mast cells (MCs) (35); altered central excitatory/inhibitory homeostasis (glutamate/gamma-aminobutyric acid) (36, 37); cortical neuromodulation (serotoninergic, noradrenergic, cholinergic, or dopaminergic) (37–40); channelopathy (41); or disturbed sodium homeostasis (42). Sterile meningeal neuroinflammation activates trigeminal primary afferents innervating the meningeal vasculature, providing a direct link to nociceptive circuits. Meningeal MCs are implicated in this mechanism, and dural MCs are directly activated in an animal model of migraine (35).
Figure 1
These candidate mechanisms also likely interact. For example, CSD is a slow, self-propagating transient wave of depolarization that suppresses activity in the cortex and is thought to underlie aura. CSD also increases meningeal blood flow and causes release of calcitonin gene-related peptide (CGRP), which may activate trigeminal nociception via the trigeminovascular system. CGRP, the main trigeminal pain mediator, is elevated in jugular blood during migraine (43). Antagonism of CGRP receptor (with olcegepant) and humanized antibodies against CGRP or its receptor are promising candidate migraine treatments.
Central Sensitization in Migraine Pathology
Central sensitization (CS) represents enhanced signaling through nociceptive pathways (caused by increases in membrane excitability and synaptic efficacy as well as reduced inhibition). CS also implies loss of the normal remarkable plasticity of the somatosensory nervous system in response to activity, inflammation, and neural injury (44). CS presents clinically as allodynia (45, 46), can persist long after an insult (47), and can be visualized by functional magnetic resonance imaging (fMRI) (48, 49).
Not surprisingly, CS is also accompanied by changes in neurotransmitters. For example, serotonin and endocannabinoids are implicated in both depression and migraine (50, 51). Decreased urinary melatonin levels are reportedly associated with chronic migraine, depression, anxiety, and fatigue (52). Migraine and many of its comorbidities share alterations in serotonin (53), noradrenaline (54–56), estrogen (57), cannabinoids (58, 59), phosphocholine-specific phospholipase C (60), and glutamate (61, 62). Medications that modulate the G-protein-coupled receptors (GPCRs) for these ligands can sometimes alleviate symptoms of both migraine and comorbidities (63, 64).
Channelopathy and Sodium Homeostasis Disturbance in Migraine
Channelopathies that alter ion homeostasis are implicated in familial hemiplegic migraine (FHM) (but not in migraine generally) as autosomal dominant mutations affecting calcium and sodium ion channels and the Na,K-ATPase transporter (65).
Ion fluctuation in CNS is exaggerated during migraine, with increased sodium concentration in the rat brain interstitial fluid during CSD (66), in cerebrospinal fluid (CSF) but not blood during migraine in humans (10), and in the brain and eyes after nitroglycerine (NTG)-triggered CS (42). These various models suggest that increased extracellular sodium, well known in CSD (66), is important in migraine and CS.
The primary control over sodium homeostasis in the nervous system is Na,K-ATPase (67, 68) that catalyzes transport of Na and K across cell membranes. Na,K-ATPase dysregulation at the neuronal and axonal plasma membrane generates abnormal local extracellular [K+] and intracellular [Na+] resulting in abnormal resting membrane potentials, axonal conduction properties (69, 70), and neuronal excitability (71). A knock-in mouse model with the FHM type 2 mutation of one Na,K-ATPase isoform has a decreased induction threshold for CSD (72). These mice do not demonstrate sexual dimorphism with regard to CSD propagation.
Dietary sodium intake, however, differs by sex in rodents, with females drinking more 3% NaCl than males. This pattern is established neonatally and can be suppressed in adult rats by testosterone (73). Neonatally androgenized females display low male-like salt intake and neonatally gonadectomized males display female-like high sodium intake (74, 75).
Pain and Sex
Fundamental differences in pain perception from person to person make objective pain measurement difficult, but it is generally accepted that males and females experience pain differently. A general impression is that women have lower pain thresholds but higher tolerance, they seek treatment and discuss pain more than men, take fewer medications, and have a higher level of daily functioning and adaptation to pain (73, 76), though this impression is not universally accepted. Importantly, differences in pain response are both biological and psychosocial, and clinical studies are not often designed to capture sex differences (76). Sex hormones are certainly involved, but other genes, for example, SRY on the Y chromosome also underlie differences in pain experience (77). Obviously, pain studies only performed in men will not necessarily translate to women, if pain is influenced by sex hormones. It is also difficult to determine if women take less opioids because of greater analgesic sensitivity or decreased tolerance of negative side effects? Considering that women predominate in chronic pain conditions [reviewed in Ref. (78)], female-focused studies should be emphasized more. Though appropriate study populations may naturally follow from patient enrollment, the theoretical and practical design of research should be sensitive to sex differences.
All Pain Is Not Created Equally
The source or location of pain is important in sexual dimorphism of pain. In a prospective interventional study using needle EMG, women rated pain higher than men, although both reported only “moderate” pain. Different muscles were associated with different pain levels, although the authors did not report if reported pain was higher in all or some muscle groups for women (79). A study of thermal pain showed the same sensitivity thresholds for men and women, but greater tolerance in men (80). Meta-analyses of pain studies are limited by small numbers of subjects, but can identify relevant features of pain: for example, in a meta-analysis of pain and analgesic requirements after ophthalmic surgery, three of four studies showed that no difference in pain by sex but a single study, including more participants than the other three, found females experienced more pain (81). Sex-based differences are not surprising given widespread expression of estrogen, progesterone, and androgen receptors in the eye (82) and brain. Notably, several ocular diseases show sex hormone-dependent changes in frequency, including glaucomas, dry eye, and central vein occlusion, but ocular pain itself is understudied in this regard (82). A study of over 15,000 patients having spinal surgery for lumbar disk herniation found more women consumed analgesics than men, reported higher levels of leg pain, lower quality of life, and higher disability (83). A meta-analysis of chronic widespread pain also showed higher incidence in women, particularly in peri- or post-menopausal women (84). Unfortunately, then, the literature contains no clear message about sex and pain, likely because of design issues, inadequate study size, retrospective design, types of surgeries analyzed, and pre-existing conditions, and difficulty quantifying pain. Clearly, we have work to do in studying pain in as standardized, objective, and controlled a way as possible (85). Even the attractiveness of the examiner can influence the pain rating by subjects (86).
Pain in Animal Studies
Useful metrics of pain for animal studies are indirect and require inference from observed actions, and cannot capture motivation behind behaviors. Behaviors that reflect pain include avoidance responses (tail withdrawal, foot removal from thermal or mechanical stimuli, blinking, and light aversion), or tending to the site of pain (licking, foot shaking after formalin injection, head grooming in migraine models, and rubbing eyes for dry eye).
Fortunately, animal studies are generally consistent with human studies. Lower thresholds for pain and increased opioid requirements for analgesic effect (behaviors) have been shown in females vs. males. Opioid efficacy also varies by genetic background in mice (87), which can reflect alterations in mu opioid receptor (μOR) binding and signaling, μOR SNPs (single nucleotide polymorphisms) or alternative molecular pathways (88). Sodium affects the stability of antagonist conformation of GPCRs, including opioid receptors (89). These observations point to studies that can lead to improved and appropriately targeted therapies.
Estrogen and Testosterone Effects in Human Migraine Animal Models
One-third to one-half of female migraineurs report worse migraines peri-menstrually, and ovulation can be a trigger. Migraine tends to lessen during pregnancy and lactation, and after menopause strongly implicating female hormone fluctuations as triggers. These observations have led to the use of both rescue and prophylaxis with all migraine-approved medications around the time of menses. Hormone therapy to reduce estrogen fluctuations may help migraine suffering, but are used cautiously because of the small increased risk of stroke in patients with migraine and aura (90). Anecdotally, changes from one birth control pill formulation to another can worsen or improve migraine. Animal experiments also support a role for sex hormones in migraine pathogenesis: female mice were more easily centrally sensitized than males, oophorectomy rendered the sexes comparable, and estrogen replacement to oopherectomized animals partially restored pain over-sensitivity (91). In male mice, orchiectomy increased CS, which was partially reversed with testosterone replacement (92). The target cells for these sex hormone actions are not clear, but imaging (93) and animal biochemistry studies (94) suggest that estrogens generally have excitatory actions on the brain while progesterone is inhibitory. (And of course the balance between them will be important.) Estrogen and progesterone increase CSD in rat cortical slices (95), possibly through modulation of excitatory glutamate release (96). Estrogen receptors are expressed in a wide variety of CNS neurons and in astrocytes; estrogen plays important and complex roles in synaptic function and neuroplasticity (97). Immune cells mediate differential mechanical pain hypersensitivity in male vs. female mice (98). Olfactory exposure to male investigators, their shirts, or to androgens and similar chemicals volatilized on sterile gauze, influences analgesia (99), and further emphasizes sexually dimorphic responses relevant to migraine.
Sex-Based Differences in Drug Responsiveness
A U.S.-wide survey showed that more women than men used over-the-counter and prescription medications (100). A national Italian survey found no difference in the use of NSAIDS or ergot derivatives but increased use of triptans in women (101) for migraine. In a Finnish population, women were prescribed more drugs of all categories to treat migraine (73). But females were at greater risk of migraine headache recurrence than men (102). Whether these drug use patterns represent differences in migraine severity, requests by patients, or perceptions of the attending clinician is unclear but the literature suggests that gender is a factor in how migraine is diagnosed and treated [reviewed in Ref. (78, 86)].
Migraine pain medications prescribed in emergency departments (ED) do not differ between men and women, with 35% treated with opioids and 1.5% treated with triptans (103). These data represent from 58,000 civilian and 9.9 million military records, but the data are not rich enough to parse out sex differences in the quality of pain or efficacy of treatment. Nonetheless, they highlight a real problem with ER treatment of migraine. Opioids may reduce migraine pain acutely, but should be avoided as they can cause episodic migraine to become chronic (104).
Opioid therapy is a notable example of sex-based differences in drug responses at many different levels. Imaging studies show differences in the response of females to μOR agonists in ligand internalization, receptor distribution, and hormonal influence. Though morphine pharmacokinetics are similar in men and women (105), PET scans show brain-region-specific differences in the magnitude of endogenous μOR activation: men have increased activation in anterior thalamus, ventral basal ganglia, and amygdala; women have reduced activation in the nucleus accumbens (106), and many studies show that females require more morphine for analgesia than males, regardless of the type or source of pain [reviewed in Ref. (107)].
Structural and Molecular Basis of Opioid Sexual Dimorphism
The mechanisms by which opioids cause transition from episodic to chronic migraine are important to understand for getting to the heart of migraine pathology. These mechanisms include increases in brainstem and cortical hyperexcitability (104). Chronic opioid administration leads to downregulation of the glutamate transporter on astrocytes, increasing the residence time of the neurotransmitter in the synaptic cleft, effectively increasing the duration of receptor activation and potentiating signaling. In cultured microglia, morphine upregulates brain-derived neurotrophic factor (BDNF), which is known to act on the NMDA receptors and influences mood disorders (108). Estrogen may play a role in this process since it mediates alterations in glutamate signaling (and glutamate modulation of CSD), uncouples μOR from downstream signaling, and estrogen metabolites are TLR4 agonists (109).
Imaging in rodents using markers of neuronal activation to either morphine or inflammatory pain show more periaqueductal gray neurons are activated in females, but fewer activated neurons project to the rostral ventromedial medulla, a circuit important for endogenous and exogenous opioid analgesia (86, 107, 110). Like CSD, this is a sex-hormone-specific effect since males feminized at birth show reduced response to morphine (111).
The estrous cycle influences both morphine-induced analgesia (greatest potency when estradiol is low) and release of CGRP (107). Estrogen can uncouple μOR from its downstream GPCR kinases and induce internalization (112). Understanding the molecular underpinnings of estrogen effects on opioid responses is important, but despite all these data and the extensive experience with morphine, it is still not possible to make general sex-based clinical recommendations for morphine administration (86, 107) in non-migraine pain states.
A surprising interaction occurs between morphine and TLR4, a receptor that recognizes bacterial lipopolysaccharide (LPS) and is localized on CNS microglia. Microglia secrete various cytokines, including IL-1, TNFα, and IFNγ, to not only neutralize bacteria but also influence pain patterns, including allodynia and hyperalgesia (113). Minocycline is a broadly used antibiotic that reduces microglia activation, indicated by reduced cytokine release (e.g., IFNγ, TNFα, and IL-1β). Minocycline potentiates morphine analgesia (113, 114), decreases p38 MAPK activation in spinal microglia (115), suppresses morphine-induced respiratory depression (114), and attenuates a morphine-dependent increase in cyclooxygenase-1 expression in cultured microglia (114). Morphine activation of TLR4 is blocked by naloxone, the μOR antagonist (116). Morphine-3-glucoronide (M3G) is a morphine metabolite that does not bind the μOR but opposes analgesic effects and enhances pain. The pain-enhancing effects of M3G can be blocked by minocycline, and IL-1 receptor antagonist and both isomers of naloxone, showing that μOR was not the direct target of minocycline (116).
Other sexually dimorphic effects related to morphine–TLR4 interactions link sex and the immune system. Intrathecal injection of LPS generates pain responses only in male mice. Removal of male sex hormones by castration reduced pain levels to those of saline controls and females, but testosterone replacement therapy in males and oophorectomy in females restored “normal” pain responses (117). Furthermore, male mice with a loss of TLR4 function display reduced pain responses typical of females. Importantly, sexually dimorphic pain responses were specific to the inducing agent and site of delivery (117). Spared nerve injury, and intrathecal injection of LPS or CFA resulted in similar sexually dimorphic responses whereas intrathecal zymosan, intracerebroventricular (ICV), or intraplantar injections of LPS elicited equivalent pain responses in males and females (117).
The Role of Mast Cells in Pain
Mast cells, a critical component of the innate immune system, are large phagocytic cells from the hematopoietic lineage. They circulate as immature cells, then mature after they settle in a tissue. In the developing brain, they localize along meningeal blood vessels (BVs) (118) and contain the vast majority of brain histamine (119). In adult life, MCs are capable of migrating across an intact blood–brain barrier (BBB) (120). In the periphery, MCs are located in various tissues, and relocate in response to inflammatory cues. They are physically associated with nerves in animals and man (121–123). In bladder, for example, ~75% of MCs are in proximity to nerve fibers facilitating nerve-immune cell communication (124). MCs are a critical component of migraine as well as migraine comorbidities (Figure 1). The initiating factors for CNS-immune system co-activation are not known, but their interactions appear to perpetuate disease (pain) in a feed-forward fashion.
Mutual Activation of the Nervous System and Mast Cells
Upon activation, MCs secrete vasoactive mediators and cytokines, including nitric oxide (NO), TNFα, vasoactive intestinal peptide (VIP), and histamine (125–129) (Figures 2 and 3). In turn, MCs react to various neuronal stimuli, such as substance P (SP), CGRP, corticotropin-releasing hormone (CRH), histamine, many of which are also associated with migraine pathophysiology (119, 130).
Figure 2
Figure 3
The physical interaction and communication between nerves and MCs is mediated by adhesion molecules, such as cell adhesion molecule (CADM1) or N-cadherin (134–136). Communication between MCs and distant neurons occurs via transgranulation or release of exosomes (137) with granule-filled pseudopods cast off on the surface of the adjacent cell. Exosomes, secreted from multivesicular bodies and fusion with the plasma membrane, released by MCs can then target more distant cells with their protein and RNA cargos (138–140).
Mast Cells and Pain Pathways
Mast cells interface in different locations outside of the CNS with nociceptors, predominantly with C-fibers. C-fibers are small, non-myelinated peripheral nerve fibers that detect noxious stimuli acid or chemical irritants (141). Once activated, C-fiber signaling is processed in the CNS to generate perceptions, such as pain, itch, urge to cough or sneeze, or subconscious activation of preganglionic autonomic neurons. For example, nociceptor activation in the gut can lead to secretion, diarrhea, and visceral pain (142–144). Additionally, local, autonomous afferent–efferent synapses independent of CNS control (“peripheral reflexes”) can transmit signals detected by a sensory nerve directly to nearby efferent enteric neurons, in gut, gallbladder, and airways (145). Neuropeptide-containing afferent C-fibers also directly regulate organ function via “axon reflexes” (146). “Axon reflexes” require the action potential of a peripheral nerve to travel until it reaches a bifurcation of the same nerve, then travel antidromically to endings of the same nerve. Once the action potential arrives, sensory neuropeptides, such as SP, neurokinin A, and CGRP, are released and can induce edema, vasodilation, smooth muscle contraction, and immune cell recruitment and activation. Thus, activation of a peripheral nerve can result in immune activation at the endings of the same nerve in a process termed “neurogenic inflammation” (146).
Mast cells are involved in pain in two ways: they secrete substances that directly activate or sensitize nociceptors (Figures 2 and 3). MCs release algogenic substances that activate nociceptors contributing to neuropathic pain (147), including trigeminocervical and lumbosacral tactile hypersensitivity (148). Sensitization of nociceptors can be mediated by MCs via histamine binding to nociceptors or nerve growth factor that binds the high-affinity nerve growth factor tropomyosin receptor kinase A (trkA) receptor (149). TrkA signaling is central to neuroprotection and neuroplasticity. Additionally, MCs secrete chemoattractants that recruit other immune cells to the site that can release pro-nociceptive factors (150).
The Role of Mast Cells in Cerebral Pain
Several lines of evidence indicate mast cell involvement in cerebral pain (Figure 2). In electrophysiological studies, MC-derived serotonin, prostaglandin I2, and to a lesser extent, histamine were identified as sensitizing agents of meningeal nociceptors (Figure 4) (133). Interestingly, the usually inflammatory eicosanoid PGD2 and leukotriene C4 did not sensitize meningeal nociceptors (133). Nerve stimulation of rat trigeminal nerve (TN) resulted in increased vascular permeability, MC activation and degranulation in the orofacial area innervated by the trigeminal nucleus (131). Neonatal rats treated with capsaicin to deplete SP have the same MC activation, degranulation, and vascular leakage upon TN stimulation as untreated animals, suggesting that SP-mediated pain signals do not work via MCs (131). On the other hand, NO donor drugs cause enhanced CGRP release in trigeminal pathways, resulting in meningeal arterial vasodilatation and MC degranulation (32).
Figure 4
A subset of chemosensitive afferent nerves of the meninges express the protease-activated receptor-2 (PAR-2 receptor), and its activation also causes vasodilatation (Figure 4) (153). Proteolytic enzymes, such as tryptase released from MCs, can activate PAR-2 receptors inducing sensitization of the transient receptor potential vanilloid 1 (TRPV1) channel (153). TRPV1 is expressed in small nociceptive neurons, including in brain dura and trigeminal ganglia. Sumatriptan inhibits TRPV1 (154). Collectively, these observations suggest that MC activation and sensitization of chemosensitive meningeal and trigeminal ganglion (TG) C-fiber nociceptors may contribute to headaches (155).
Stress is a common trigger for migraines. Stress activation of brain MCs in rats is mediated, in part, by corticotropin-releasing factor (CRF) (130). Stress also selectively increases BBB permeability in rodents in brain regions rich in mast cells (156). Increased serum histamine levels in patients with migraines or cluster headaches further suggest MC degranulation during headache (157).
Primary MC disease (systemic mastocytosis or MC activation syndrome) is associated with symptoms of “brain fog”: loss of attention, focus, short-term memory, and ability to multitask (158, 159), underlining the connection between the innate immune system and the CNS.
Mast Cells and Sex Hormones
Both estrogen and progesterone can activate MCs (160). Human and mouse brain MCs express estrogen receptors ERα and ERβ and/or the progesterone receptors A (PR-A) and B (PR-B) [reviewed in Ref. (160), Figure 2]. Steroid receptors are located at the plasma membrane or the nucleus (160). Upon binding hormone, nuclear steroid receptors form multiprotein complexes that determine whether the complex acts as a transcriptional repressor or enhancer (161). Steroid receptors located at the plasma membrane or on organelle membranes, by contrast, induce immediate signaling. Receptor location thereby determines the temporal relationship between hormone exposure and hormone-triggered effects. Nuclear receptor-mediated effects take minutes to hours, while plasma membrane and organelle-receptor mediated effects take seconds to minutes (160, 161).
Mast cell degranulation is a rapid response to estrogen or progesterone. Importantly, though androgen receptors are expressed in human MCs, testosterone does not mediate MC degranulation (162). In rats, MC densities in dura correlate with the availability of estrogen: males and ovariectomized females display the lowest density, while estrogen treatment of ovariectomized females increases dural MC density to that in intact females (163). MC numbers are modified by splenectomy, indicating that MCs migrate from spleen or that spleen promotes mobilization and migration of MCs (163). Though not well studied, it is also possible that MC phenotype is altered by the splenic environment as in other immune cells. Experimentally, MC degranulation is not impacted by either the estrus cycle of intact females or estrogen administration of oophorectomized females (163).
Other immune cells are also equipped with receptors for estrogen, progesterone, and other sex steroids but sex steroid effect on these cells is largely unstudied (164). So how other immune cells impact migraine is an open question, but their role in some migraine comorbidities is prominent. In allergies and asthma, allergen binding antibodies are a key component of the disease and all cells involved in the generation of antibodies (T cells, antigen-presenting cells, B cells, and regulatory T cells) express sex steroid receptors and can be modulated by these factors (164). Both the xenoestrogen bisphenol A (an environmental estrogen-like compound) and estradiol enhance differentiation of antigen-presenting cells that preferentially promote activation of T cells into the Th2 phenotype involved in antibody production (165, 166).
Environmental Estrogens and Mast Cell Function
Mast cells have been extensively studied in the context of asthma, allergies, and anaphylaxis, largely with the help of well-defined rodent models. In those models, xenoestrogens promote MC degranulation and activation (167). Xenoestrogens are present in water and food in low concentration, concentrating up the foodchain and retaining bioactivity for long periods (167). In human, MC lines, xenoestrogens can induce MC degranulation, and their effects are additive with other xenoestrogens or estrogens (167, 168). Importantly, estrogen enhancement of degranulation was also observed in the setting of IgE-triggered MC degranulation characteristic of allergic reactions (167, 168). Xenoestrogen modulation of MC function in the context of diseases, such as migraine, has not been studied, but in a rat model, migraine behaviors were exacerbated by exposure to bisphenol A (169). Some researchers suspect that migraine incidence is increasing (170), and others have reported associations between air pollution and migraine (171) as well as urticaria reactions (172), raising questions about environmental pollutants generally in migraine triggering.
Fluid Balance and Sexual Dimorphism in Migraine
Over-hydration or dehydration is common migraine triggers. Fluid homeostasis is influenced significantly by fluctuating gonadal steroids that change through the menstrual cycle or with hormone replacement therapy. Estrogen receptor expression is prominent in brain nuclei critical for maintaining fluid balance. The estrogen receptor ERβ is present in the vasopressin magnocellular neuroendocrine cells (MNCs) of the hypothalamus, while estrogen receptor ERα is present in the sensory circumventricular organs (CVO) (173). In hyponatremia, AVP release is strongly inhibited in the MNCs, while ERβ expression is increased (174, 175). ERβ expression is reduced in hyperosmolar states, in response to neuronal activation (175).
The renin–angiotensin–aldosterone system (RAS) plays a pivotal role in regulating blood pressure and fluid balance, targeting capillary endothelium and neurons throughout the brain (176) to regulate cerebral blood flow and stress responses (177). The angiotensin2 (AT2) receptor gene is regulated by estrogen and plays a critical role in blood pressure regulation in females (178). The RAS acts through the CVOs and the area postrema to activate pathways that elevate blood pressure, release vasopressin and aldosterone, and increase ingestion of water and sodium. The sensory CVOs, the subfornical organ, and organum vasculosum of the lamina terminalis (OVLT) lack a BBB and so are particularly sensitive to humoral signals, including plasma and CSF sodium, osmolarity, and AT2 levels (see below). Drugs that act on the RAS can help some migraineurs (179), but more extensive trials are needed to generalize these observations. High plasma ACE activity has been reported in the blood of migraineurs (180), suggesting that the RAS is disturbed. Nonetheless, ACE genotype polymorphisms have not been extensively studied for migraine therapeutic implications (181, 182). Activation of AT1 increases CGRP release from the dorsal root ganglia sensory neurons of spontaneously hypertensive rats (183), indicating another link between RAS modulation and migraine. Elevated plasma levels of CGRP found in migraineurs have led to development of CGRP antagonists and monoclonal antibody therapies with potential to rescue migraine (32).
The Blood–Brain Barrier, Sex, and Migraine
The BBB is a highly selective unit that maintains brain homeostasis by limiting peripheral circulatory substances from entering the CNS (184). The functional neurovascular unit of the BBB is made of endothelial cells, pericytes, and astrocytes (185). Disruption in BBB function can lead to various neurological problems and has recently been implicated in pain disorders (186). The specialized tight and gap junctions between BBB endothelial cells prevent entry of toxins, and allow only small and lipophilic molecules into the CNS (185). The vascular theory of migraine, first articulated by Wolff (1948) implicates vasodilation of cranial arteries as the cause of the migraine pain (187). The role of the neurovascular unit has been heavily studied in relation to migraine but is still a source of debate (188–190).
The meninges are an interface between the systemic immune system and the CNS (Figure 2) with the relative immune privilege of the CNS maintained by the BBB. Traditionally, absence of a lymphatic system was also considered a key component of immune privilege. However, lymphatic systems in the immune privileged posterior eye, blind-ended were recently detected in humans (191). Additionally, a murine CNS lymphatic system was recently identified (192). This network is likely involved in CSF drainage, carries immune cells, and drains to the deep cervical lymph nodes. These recent advances in neuroimmunology are likely very relevant to migraine pathophysiology.
The BBB and Migraine
Blood–brain barrier alteration in migraine is an area of intense study (193). In FHM type II, BBB disruption can be demonstrated using contrast-enhanced MRI (194). Other direct evidence of BBB dysfunction during migraine was observed in CSD rodent models. Increased cerebral cortex levels of metalloprotein 9 (MMP-9), a protease marker of BBB, were observed with associated edema and plasma protein leakage into brain (195). Increased plasma MMP-9 has also been implicated in migraine pathogenesis (196, 197). Women migraineurs have increased plasma MMP-9 concentrations during headache vs. interictal phases, and a particular MMP-9 haplotype (198). In order to compensate for a sudden substantial increase in CBF during migraine attacks, MMPs are thought to compensate by loosening TJs and expanding the BBB extracellular matrix (199), resulting in an inflammatory environment contributing to migraine (195).
Calcitonin gene-related peptide, a major player in migraine, causes dilation of the middle meningeal artery (MMA) in healthy volunteers, and sumatriptan reverses this dilation (22). Of note, pharmacokinetic parameters of triptans vary according to gender, with generally higher bioavailability in women and higher clearance rate in men (200). Gender-dependent dermal blood flow differences from capsaicin-induced release of CGRP (201) points to a specific mechanism underlying sexual dimorphism of migraine incidence.
Migraine Comorbidities and Sex
Many of the extensive range of known migraine comorbidities and their overlapping genetic, molecular, and drug responses are reportedly more frequent in females (202), though not uniformly. One study showed that males tended to have more physical comorbid disorders, whereas females had more psychiatric comorbidities (8). Stress-related disorders are especially more common in females, including migraine, depression, and anxiety. Two groups of diseases with strong immunological components are also more prominent in women migraineurs: allergies and some autoimmune disorders. While environmental allergies are significantly higher in both men and women migraineurs compared to non-migraineurs, asthma is more frequent only in women migraineurs (202). Both osteoarthritis (driven by inflammation) and autoimmune rheumatoid arthritis are more prominent in women migraineurs. Similarly, different forms of autoimmune thyroid diseases are more prominent in women migraineurs than non-migraineurs, while male migraineurs are similar in this regard to male non-migraineurs.
In search of the basis for the sexual dimorphism of psychiatric disorders in women migraineurs, the locus coeruleus (LC)–norepinephrine (NE) neurons display more extensive dendritic arborization in female rats vs. male rats (203). Clinically, hormone fluctuations are clearly involved in peri-menstrual, menopausal, and postpartum depression. IC/BPS, IBS, and asthma are more common in females. Vestibular migraine is surprisingly common affecting about 1% of the population, and also has a female preponderance (204).
The neurovascular theory of migraine is in part supported by a positive correlation between Raynaud’s phenomenon and migraine (205). Systemic sclerosis is more common in females (206), as is hypothyroidism (207), and SLE, with potential sex-specific differences mediated by estrogen and its metabolites, decreased androgen levels, hyperprolactinemia, and gonadotrophic-release hormones (208). Prolactin, important in pregnancy and lactation, also affects angiogenesis, immune function, and osmoregulation in both sexes (209) and hyperprolactinemia has been linked to headache (210).
Interstitial Cystitis/Bladder Pain Syndrome
Migraine is common in patients with IC/BPS. About 11% of women and 5% of men suffer from IC/BPS (211, 212) and, like migraine, it is more common in people with other pain conditions, including IBS and fibromyalgia, both more common in females (213, 214). Imaging has shown overlapping areas of involvement of brain regions of the salience, emotional response, and sensorimotor networks, and the prefrontal cortex in IC/BPS and other chronic visceral pain conditions (215, 216) IC is often diagnosed when urinary frequency, nocturia, and suprapubic pain are exacerbated by ovulation and under stress. Bladder MCs are activated in IC (217).
Bladder nerves include sensory afferents and autonomic efferents, and peptidergic, P2X-, and TRPV1 fibers from the lumbosacral dorsal root ganglion (DRG), along with adrenergic and cholinergic fibers. Numerous mechano- and nociceptive receptors have been described that respond to a variety of inputs, including EGF, SP, CGRP, CRF, acetylcholine, noradrenaline, adenosine, and inflammatory cells. Urothelial cells secrete many transmitters and mediators, including ATP (218), acetylcholine, prostaglandins, NO, and cytokines. Importantly, the bladder expresses both ERα and ERβ receptors and preclinical models show that E2 modulation of stress-activated kinase p38 MAPK varies during the menstrual cycle (219).
Allergy and Asthma
Asthma and other allergic airway diseases are a prominent example of MC-driven diseases with higher propensity in females: similar to migraine, women are approximately three times more affected than men (220–222). Thirty to forty percent of women experience exacerbation of asthma symptoms peri-menstrually (223). Similar to cerebral pain sensitization patterns as a function of estrogen (91), oophorectomized animals have reduced airway inflammation (224) and tamoxifen (ER antagonist) treatment of intact females also reduced airway inflammation (224).
Mast cells activated by binding of allergen–antibody IgE complexes directly stimulate C-fibers that express receptors for many mediators present in the context of allergic disorders. This direct connection has been shown for airways, skin, gastrointestinal tract, and bladder (196, 197, 225, 226). Similarly, intestinal MC activation can sensitize spinal nerves such that a short-lived mechanical gut distension results in prolonged afferent nerve activation (227). This allergen activation of MCs can result in C-fibers hyperexcitability, lasting for several hours (228). Importantly, allergies, which trigger symptoms in the periphery, can also modulate CNS neurons, and contribute to CS (229). There is currently no evidence that CNS MCs are activated by peripheral allergen exposure and, thus, it is more likely that the strong peripheral nociceptor activity modulates CNS neurons via the release of peptides and transmitters at the central terminals of the afferent nerves. Thus, migraine and its prominent comorbidity, allergy, have a common denominator in MCs and triggering of one disease may exacerbate the other.
Irritable Bowel Syndrome
GI inflammation is painful and leads to profound changes in CNS (230). Conversely migraine is more prevalent in patients with celiac or IBD than in the general population (231). GI inflammation invariably leads to disordered motility. With inflammation, neurons involved in peristalsis become hyperexcitable, and inhibitory neurotransmission is blunted (232). These changes can persist (in the spinal cord dorsal horn) even after GI inflammation has subsided. Abdominal migraine is distinct from inflammatory bowel diseases (or celiac disease or sickle cell disease that present in similar ways). Abdominal migraine pain is episodic and severe enough to prompt ER visits, most commonly in children. A case report suggests that pregnancy can interrupt the progression of abdominal migraine (233).
Mast cells contribute to IBS, a common comorbidity of migraine (234–236). Increases in intestinal neuron excitability, mesenteric sensory nerve activity, and visceral or somatic sensitivity possibly caused by intestinal mucosa serotonin, histamine, and MC tryptase contribute to IBS pathology (237) In the long term, the bowel nervous system responds by increasing expression of SP and TRPV1 and, therefore, bowel pain perception (132, 225, 238–240). MC infiltration of the colonic mucosa in IBS patients also correlates with the amount of released NGF, neuronal sprouting, and expression of the NGF receptor NTRK1 (241).
Other gastrointestinal motility disorders that share their comorbidity and a sexual proclivity for females with migraine include gastroparesis (242), cyclic vomiting syndrome (243), and infant colic (244). Colic is more common in offspring of mothers with migraine (245).
Osteoarthritis and Rheumatoid Arthritis
Synovial inflammation is as an important feature of osteoarthritis and pain is its main symptom. Both peripheral and central neurological mechanisms are involved and, hence, osteoarthritis is considered a chronic nociceptive pain condition (246). In rheumatoid arthritis, joint pain is also the main symptom (247). Synovial inflammation in osteoarthritis presents with infiltration of macrophages, T cells, and MCs but the overall level of infiltration and cytokine production is lower than that in rheumatoid arthritis (248). The common denominator of osteoarthritis and migraine is nociceptive sensitization.
The pathogenesis of rheumatoid arthritis is not fully understood but involves both the innate and adaptive arms of the immune system eventually resulting in the breakdown of immune tolerance, autoantigen presentation, and both T and B cell activation (249). Interestingly, MMP-9 is a genetic marker of RA susceptibility and contributes to joint damage (250). As noted above, MMP-9 plays a role in migraine, and serum levels are generally elevated in migraineurs.
Anxiety
Anxiety, including panic attacks, affects nearly one in five adults in the U.S. (251), but is even more frequent in migraineurs. Women are significantly more likely than men to develop an anxiety disorder (252). The National Comorbidity Survey (NCS, conducted from 1990 to 1992) found that lifetime prevalence rates for any anxiety disorder were 30.5% for women and 19.2% for men (253). Prevalence rates were also higher in women than men for each anxiety disorder examined (253, 254).
Anxiety is associated with an exaggerated sympathetic nervous system response, beginning with the hypothalamic–pituitary–adrenal (HPA) axis (255), with CRF secretion. The end products of this cascade are cortisol, epinephrine, and NE (256). Anxiety also results in glucocorticoid receptor resistance. Without appropriate cortisol regulation of the local cytokine response, there is greater susceptibility to compromised immune defenses (257).
Depression Is a Common Migraine Comorbidity
Population-based and clinical studies have demonstrated the high prevalence of migraine and depression as comorbid disorders. Migraineurs are 2.2–4 times more likely to suffer from depression (258), and 28% of migraineurs experience major depressive disorder (MDD) (259), more common in migraineurs with aura (260). Rates of suicide attempt are also increased in migraineurs (261) and migraineurs with fibromyalgia. MDD patients with active migraine are particularly difficult to treat (262).
Moreover, migraine and depression are two to three times more common in women than men (254, 263). The relationship between migraine and depression appears to be bidirectional, suggesting a common neurobiology (264). Women with CDH are more likely to suffer from MDD than those with episodic headaches (265). Furthermore, episodic migraineurs with depression are at increased risk of developing chronic migraine (266). A few pathophysiological mechanisms linking the two disorders have been suggested: hormonal influences (58), serotonergic dysfunction, CS, and Na+,K+-ATPase dysregulation (9, 267, 268), all of which are controlled in part by estrogen or show gender-specific differences.
Women’s increased migraine attacks and mood disturbances have been linked with fluctuations in estrogen during menses, postpartum, and premenopausal periods (269). Anecdotally, estrogen augmentation can have potential positive therapeutic effects on depression (57). Physiological effects of estrogen span both disorders, including the modulation of neuropeptide Y, CRH, and the neurotransmitters serotonin, dopamine, and glutamate (57).
A serotonergic dysfunction associated with migraine has been linked with polymorphisms in the serotonin transporter 5-HT (270). An allele of 5-HT that slows serotonin synthesis is associated with increased susceptibility to depression and increased sensitivity to anxiety and stress (271). Chronically low serotonin is also implicated in CSD and heightened sensitivity of the trigeminovascular pathways of migraine (272). Depression and anxiety, associated with reduced serotonin are commonly treated with pharmaceuticals that increase central serotonin levels, some of which have also been used in treatment of migraine (273), thought SSRIs are not universally effective in migraine (15, 272, 274). Low-dose TCAs can also treat migraine, both rescue and prophylaxis in some patients (275) and other pain syndromes. Women tend to respond better to treatment with SSRIs due to hormone-dependent pharmacokinetics (276). Thus, anti-depressants, triptans, and anticonvulsants are often used in combination in treatment of both disorders (277, 278). Behavioral therapy also has a place in treating both migraine and depression (279) but despite these options, treatment of these two disorders is still challenging (280).
Allodynia, a clinical marker of CS, is correlated with increased risk of depression among migraineurs (281), and increased suicidal ideation (282). Pain perception is abnormal in patients with MDD, who display lowered pain threshold and tolerance (283).
As mentioned earlier, in some cases, migraine and depression progress into chronic states more refractory to treatment (262, 265, 266), suggesting a common CS syndrome, involving both emotional and sensory pathways (284, 285). Women have been shown to be more susceptible to stress and negative experiences, a well-known risk factor for depression and migraine (286). Chronic stress induces neuroinflammation (287). Activation or dysregulation of the HPA has also been implicated in migraine and depression (288, 289). Furthermore, estrogen receptors are abundant and localized in the hypothalamus. Animal studies have shown that females with high estrogen activity had a greater HPA axis response to stress compared to low-estrogen counterparts and males (290).
Inflammation is possibly the mechanistic link between depression and migraine, potentially due to proinflammatory cytokine alteration of tryptophan (TRP) metabolism, reducing 5-HT synthesis and activating the HPA axis (291). ER-β signaling increases 5-HT synthesis in murine brain (292). Clinically, depression symptomatology is linked to depletion of 5-HT and production of TRP metabolites by inflammatory cytokines (293). The role of CGRP in migraine, inflammation, and sexual dimorphism as noted above is also observed in patients with MDD (294).
Na+,K+-ATPase dysfunction in migraine has been discussed above. Reduced Na+,K+-ATPase activity contributes to both mania and depression (267, 295–297), likely through increased neuronal excitability and decreased neurotransmitter release (297). Mice lacking the Na+,K+-ATPase subunit FXDY2 have altered renal sodium handling and increased thermal instability (298). FXDY2 activity has also been proposed as a modulator of hypersensitivity to pain induced by inflammation (298).
Conclusion
Common threads in migraine and comorbid conditions are sexual dimorphism, MC effectors, and neuronal hyperexcitability. We note these common features in hopes that immunologists, endocrinologists, and other domain experts in experimental and clinical neurosciences can inform each other. For example, the detailed understanding of MC dysregulation in asthma and allergy may help inform the pathogenesis of migraine. Awareness of the altered sodium homeostasis found in migraine may encourage studies of sodium homeostasis underlying some of the more common migraine morbidities that are often viewed within their clinical specialties as unrelated to migraine. Awareness of the prevalence of migraine, especially in women, should help inform the way histories are taken outside of neurology and headache clinics. Most importantly, understanding the common drivers of disease may help re-define the subtypes of migraine and its comorbidities: are MC-mediated migraines fundamentally different than those in which sodium dysregulation is a major driver? Current therapies are crude, non-specific, and must be highly individualized. Design of more rational therapies likely involves better phenotyping of migraine by gender-specific and other pathophysiological drivers of disease, and will certainly involve multidisciplinary input from psychiatry and pain specialists, allergists, and gastroenterologists, in dialog with neuroscientists.
Statements
Author contributions
All authors contributed to writing of the manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
ScherAIBigalMELiptonRB. Comorbidity of migraine. Curr Opin Neurol (2005) 18(3):305–10.10.1097/01.wco.0000169750.52406.a2
2
SilbersteinSD. Cardiovascular risk factors associated with migraine. Lancet Neurol (2005) 4(7):391–2.10.1016/S1474-4422(05)70103-4
3
SilbersteinSDLiptonRBBreslauN. Migraine: association with personality characteristics and psychopathology. Cephalalgia (1995) 15(5):358–69; discussion 36.10.1046/j.1468-29821995.1505358.x
4
BuzziMGColognoDFormisanoR. Migraine disease: evolution and progression. J Headache Pain (2005) 6(4):304–6.10.1007/s10194-005-0215-9
5
ColognoDBuzziMGCarlesimoGACicinelliPCostaAFaddaLet alPsychiatric disorders and pain location in unilateral migraineurs. J Headache Pain (2005) 6(4):227–30.10.1007/s10194-005-0192-z
6
GloverVJarmanJSandlerM. Migraine and depression: biological aspects. J Psychiatr Res (1993) 27(2):223–31.10.1016/0022-3956(93)90010-Y
7
WauquierA. Is there a common pharmacological link between migraine and epilepsy?Funct Neurol (1986) 1(4):515–20.
8
TietjenGEHerialNAHardgroveJUtleyCWhiteL. Migraine comorbidity constellations. Headache (2007) 47(6):857–65.10.1111/j.1526-4610.2007.00814.x
9
HarringtonMGFontehANArakakiXCowanRPEckeLEFosterHet alCapillary endothelial Na(+), K(+), ATPase transporter homeostasis and a new theory for migraine pathophysiology. Headache (2010) 50(3):459–78.10.1111/j.1526-4610.2009.01551.x
10
HarringtonMGFontehANCowanRPPerrineKPogodaJMBiringerRGet alCerebrospinal fluid sodium increases in migraine. Headache (2006) 46(7):1128–35.10.1111/j.1526-4610.2006.00445.x
11
SchytzHWHolstHArendt-NielsenLOlesenJAshinaM. Cutaneous nociception and neurogenic inflammation evoked by PACAP38 and VIP. J Headache Pain (2010) 11(4):309–16.10.1007/s10194-010-0214-3
12
TassorelliCGrecoRArmenteroMTBlandiniFSandriniGNappiG. A role for brain cyclooxygenase-2 and prostaglandin-E2 in migraine: effects of nitroglycerin. Int Rev Neurobiol (2007) 82:373–82.10.1016/S0074-7742(07)82020-4
13
CuiYKataokaYLiQHYokoyamaCYamagataAMochizuki-OdaNet alTargeted tissue oxidation in the cerebral cortex induces local prolonged depolarization and cortical spreading depression in the rat brain. Biochem Biophys Res Commun (2003) 300(3):631–6.10.1016/S0006-291X(02)02906-6
14
HollandSSilbersteinSDFreitagFDodickDWArgoffCAshmanEet alEvidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology (2012) 78(17):1346–53.10.1212/WNL.0b013e3182535d0c
15
SilbersteinSDHollandSFreitagFDodickDWArgoffCAshmanEet alEvidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology (2012) 78(17):1337–45.10.1212/WNL.0b013e3182535d20
16
BeckerWJ. Acute migraine treatment. Continuum (Minneap Minn) (2015) 21(4 Headache):953–72.10.1212/CON.0000000000000192
17
BeckerWJ. Acute migraine treatment in adults. Headache (2015) 55(6):778–93.10.1111/head.12550
18
Nierenburg HdelCAilaniJMalloyMSiavoshiSHuNNYusufN. Systematic review of preventive and acute treatment of menstrual migraine. Headache (2015) 55(8):1052–71.10.1111/head.12640
19
SotocinalSGSorgeREZaloumATuttleAHMartinLJWieskopfJSet alThe Rat Grimace Scale: a partially automated method for quantifying pain in the laboratory rat via facial expressions. Mol Pain (2011) 7:55.10.1186/1744-8069-7-55
20
MatsumiyaLCSorgeRESotocinalSGTabakaJMWieskopfJSZaloumAet alUsing the Mouse Grimace Scale to reevaluate the efficacy of postoperative analgesics in laboratory mice. J Am Assoc Lab Anim Sci (2012) 51(1):42–9.
21
MalekiNLinnmanCBrawnJBursteinRBecerraLBorsookD. Her versus his migraine: multiple sex differences in brain function and structure. Brain (2012) 135(Pt 8):2546–59.10.1093/brain/aws175
22
MalekiNBecerraLNutileLPendseGBrawnJBigalMet alMigraine attacks the Basal Ganglia. Mol Pain (2011) 7:71.10.1186/1744-8069-7-71
23
MalekiNBecerraLBrawnJBigalMBursteinRBorsookD. Concurrent functional and structural cortical alterations in migraine. Cephalalgia (2012) 32(8):607–20.10.1177/0333102412445622
24
MalekiNBecerraLBrawnJMcEwenBBursteinRBorsookD. Common hippocampal structural and functional changes in migraine. Brain Struct Funct (2013) 218(4):903–12.10.1007/s00429-012-0437-y
25
MoultonEABecerraLBorsookD. An fMRI case report of photophobia: activation of the trigeminal nociceptive pathway. Pain (2009) 145(3):358–63.10.1016/j.pain.2009.07.018
26
LeonardiMSteinerTJScherATLiptonRB. The global burden of migraine: measuring disability in headache disorders with WHO’s classification of functioning, disability and health (ICF). J Headache Pain (2005) 6(6):429–40.10.1007/s10194-005-0252-4
27
DaiZZhongJXiaoPZhuYChenFPanPet alGray matter correlates of migraine and gender effect: a meta-analysis of voxel-based morphometry studies. Neuroscience (2015) 299:88–96.10.1016/j.neuroscience.2015.04.066
28
PietrobonDMoskowitzMA. Pathophysiology of migraine. Annu Rev Physiol (2013) 75:365–91.10.1146/annurev-physiol-030212-183717
29
CharlesA. Does cortical spreading depression initiate a migraine attack? Maybe not. Headache (2010) 50(4):731–3.10.1111/j.1526-4610.2010.01646.x
30
ZhangXLevyDKainzVNosedaRJakubowskiMBursteinR. Activation of central trigeminovascular neurons by cortical spreading depression. Ann Neurol (2011) 69(5):855–65.10.1002/ana.22329
31
ZhangXLevyDNosedaRKainzVJakubowskiMBursteinR. Activation of meningeal nociceptors by cortical spreading depression: implications for migraine with aura. J Neurosci (2010) 30(26):8807–14.10.1523/JNEUROSCI.0511-10.2010
32
MesslingerKLennerzJKEberhardtMFischerMJ. CGRP and NO in the trigeminal system: mechanisms and role in headache generation. Headache (2012) 52(9):1411–27.10.1111/j.1526-4610.2012.02212.x
33
BuzziMGMoskowitzMA. The trigemino-vascular system and migraine. Pathol Biol (Paris) (1992) 40(4):313–7.
34
MarkowitzSSaitoKBuzziMGMoskowitzMA. The development of neurogenic plasma extravasation in the rat dura mater does not depend upon the degranulation of mast cells. Brain Res (1989) 477(1–2):157–65.10.1016/0006-8993(89)91403-0
35
LevyDBursteinRKainzVJakubowskiMStrassmanAM. Mast cell degranulation activates a pain pathway underlying migraine headache. Pain (2007) 130(1–2):166–76.10.1016/j.pain.2007.03.012
36
RobertCBourgeaisLArretoCDCondes-LaraMNosedaRJayTet alParaventricular hypothalamic regulation of trigeminovascular mechanisms involved in headaches. J Neurosci (2013) 33(20):8827–40.10.1523/JNEUROSCI.0439-13.2013
37
SiniatchkinMSendackiMMoellerFWolffSJansenOSiebnerHet alAbnormal changes of synaptic excitability in migraine with aura. Cereb Cortex (2012) 22(10):2207–16.10.1093/cercor/bhr248
38
AntalALangNBorosKNitscheMSiebnerHRPaulusW. Homeostatic metaplasticity of the motor cortex is altered during headache-free intervals in migraine with aura. Cereb Cortex (2008) 18(11):2701–5.10.1093/cercor/bhn032
39
CharbitARAkermanSGoadsbyPJ. Trigeminocervical complex responses after lesioning dopaminergic A11 nucleus are modified by dopamine and serotonin mechanisms. Pain (2011) 152(10):2365–76.10.1016/j.pain.2011.07.002
40
SunYGPita-AlmenarJDWuCSRengerJJUebeleVNLuHCet alBiphasic cholinergic synaptic transmission controls action potential activity in thalamic reticular nucleus neurons. J Neurosci (2013) 33(5):2048–59.10.1523/JNEUROSCI.3177-12.2013
41
CreggRMominARugieroFWoodJNZhaoJ. Pain channelopathies. J Physiol (2010) 588(Pt 11):1897–904.10.1113/jphysiol.2010.187807
42
HarringtonMGChekmenevEYSchepkinVFontehANArakakiX. Sodium MRI in a rat migraine model and a NEURON simulation study support a role for sodium in migraine. Cephalalgia (2011) 31(12):1254–65.10.1177/0333102411408360
43
HoTWEdvinssonLGoadsbyPJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol (2010) 6(10):573–82.10.1038/nrneurol.2010.127
44
LatremoliereAWoolfCJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain (2009) 10(9):895–926.10.1016/j.jpain.2009.06.012
45
BursteinRCutrerMFYarnitskyD. The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain (2000) 123(Pt 8):1703–9.10.1093/brain/123.8.1703
46
SelbyGLanceJW. Observations on 500 cases of migraine and allied vascular headache. J Neurol Neurosurg Psychiatry (1960) 23:23–32.10.1136/jnnp.23.1.23
47
BasbaumAIBautistaDMScherrerGJuliusD. Cellular and molecular mechanisms of pain. Cell (2009) 139(2):267–84.10.1016/j.cell.2009.09.028
48
LeeMCZambreanuLMenonDKTraceyI. Identifying brain activity specifically related to the maintenance and perceptual consequence of central sensitization in humans. J Neurosci (2008) 28(45):11642–9.10.1523/JNEUROSCI.2638-08.2008
49
MoultonEABursteinRTullySHargreavesRBecerraLBorsookD. Interictal dysfunction of a brainstem descending modulatory center in migraine patients. PLoS One (2008) 3(11):e3799.10.1371/journal.pone.0003799
50
WelchSP. Interaction of the cannabinoid and opioid systems in the modulation of nociception. Int Rev Psychiatry (2009) 21(2):143–51.10.1080/09540260902782794
51
SugiuraT. Physiological roles of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Biofactors (2009) 35(1):88–97.10.1002/biof.18
52
MasruhaMRLinJde Souza VieiraDSMinettTSCipolla-NetoJZukermanEet alUrinary 6-sulphatoxymelatonin levels are depressed in chronic migraine and several comorbidities. Headache (2010) 50(3):413–9.10.1111/j.1526-4610.2009.01547.x
53
MarinoEFannyBLorenziCPirovanoAFranchiniLColomboCet alGenetic bases of comorbidity between mood disorders and migraine: possible role of serotonin transporter gene. Neurol Sci (2010) 31(3):387–91.10.1007/s10072-009-0183-y
54
MartinezFCastilloJPardoJLemaMNoyaM. Catecholamine levels in plasma and CSF in migraine. J Neurol Neurosurg Psychiatry (1993) 56(10):1119–21.10.1136/jnnp.56.10.1119
55
BurrRLJarrettMECainKCJunSEHeitkemperMM. Catecholamine and cortisol levels during sleep in women with irritable bowel syndrome. Neurogastroenterol Motil (2009) 21(11):1148–e97.10.1111/j.1365-2982.2009.01351.x
56
RichterFMikulikOEbersbergerASchaibleHG. Noradrenergic agonists and antagonists influence migration of cortical spreading depression in rat-a possible mechanism of migraine prophylaxis and prevention of postischemic neuronal damage. J Cereb Blood Flow Metab (2005) 25(9):1225–35.10.1038/sj.jcbfm.9600120
57
PeterlinBLKatsnelsonMJCalhounAH. The associations between migraine, unipolar psychiatric comorbidities, and stress-related disorders and the role of estrogen. Curr Pain Headache Rep (2009) 13(5):404–12.10.1007/s11916-009-0066-1
58
AvielloGRomanoBIzzoAA. Cannabinoids and gastrointestinal motility: animal and human studies. Eur Rev Med Pharmacol Sci (2008) 12(Suppl 1):81–93.
59
RussoEB. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?Neuro Endocrinol Lett (2004) 29(2):192–200.
60
FontehANPogodaJMChungRCowanRPHarringtonMG. Phospholipase C activity increases in cerebrospinal fluid from migraineurs in proportion to the number of comorbid conditions: a case-control study. J Headache Pain (2013) 14:60.10.1186/1129-2377-14-60
61
FerrariASpaccapeloLPinettiDTacchiRBertoliniA. Effective prophylactic treatments of migraine lower plasma glutamate levels. Cephalalgia (2009) 29(4):423–9.10.1111/j.1468-2982.2008.01749.x
62
AmilhonBLepicardERenoirTMongeauRPopaDPoirelOet alVGLUT3 (vesicular glutamate transporter type 3) contribution to the regulation of serotonergic transmission and anxiety. J Neurosci (2010) 30(6):2198–210.10.1523/JNEUROSCI.5196-09.2010
63
GoadsbyPJSprengerT. Current practice and future directions in the prevention and acute management of migraine. Lancet Neurol (2010) 9(3):285–98.10.1016/S1474-4422(10)70005-3
64
CulpepperL. Generalized anxiety disorder and medical illness. J Clin Psychiatry (2009) 70(Suppl 2):20–4.10.4088/JCP.s.7002.04
65
TolnerEAHoubenTTerwindtGMde VriesBFerrariMDvan den MaagdenbergAM. From migraine genes to mechanisms. Pain (2015) 156(Suppl 1):S64–74.10.1097/01.j.pain.0000460346.00213.16
66
KraigRPNicholsonC. Extracellular ionic variations during spreading depression. Neuroscience (1978) 3(11):1045–59.10.1016/0306-4522(78)90122-7
67
AstrupJSorensenPMSorensenHR. Oxygen and glucose consumption related to Na+-K+ transport in canine brain. Stroke (1981) 12(6):726–30.10.1161/01.STR.12.6.726
68
WhittamR. The dependence of the respiration of brain cortex on active cation transport. Biochem J (1962) 82:205–12.10.1042/bj0820205
69
ParnasIHochsteinSParnasH. Theoretical analysis of parameters leading to frequency modulation along an inhomogeneous axon. J Neurophysiol (1976) 39(4):909–23.
70
SpiraMEYaromYParnasI. Modulation of spike frequency by regions of special axonal geometry and by synaptic inputs. J Neurophysiol (1976) 39(4):882–99.
71
ArakakiXFosterHSuLDoHWainAJFontehANet alExtracellular sodium modulates the excitability of cultured hippocampal pyramidal cells. Brain Res (2011) 1401:85–94.10.1016/j.brainres.2011.05.037
72
LeoLGherardiniLBaroneVDe FuscoMPietrobonDPizzorussoTet alIncreased susceptibility to cortical spreading depression in the mouse model of familial hemiplegic migraine type 2. PLoS Genet (2011) 7(6):e1002129.10.1371/journal.pgen.1002129
73
SumelahtiMLMattilaKSillanmakiLSumanenM. Prescription patterns in preventive and abortive migraine medication. Cephalalgia (2011) 31(16):1659–63.10.1177/0333102411427602
74
KrecekJ. The pineal gland and the development of salt intake patterns in male rats. Dev Psychobiol (1976) 9(2):181–8.10.1002/dev.420090211
75
KrecekJNovakovaVStibralK. Sex differences in the taste preference for a salt solution in the rat. Physiol Behav (1972) 8(2):183–8.10.1016/0031-9384(72)90358-7
76
Ramirez-MaestreCEsteveR. The role of sex/gender in the experience of pain: resilience, fear, and acceptance as central variables in the adjustment of men and women with chronic pain. J Pain (2014) 15(6):608.e–18.e.10.1016/j.jpain.2014.02.006
77
NgunTCGhahramaniNSanchezFJBocklandtSVilainE. The genetics of sex differences in brain and behavior. Front Neuroendocrinol (2011) 32(2):227–46.10.1016/j.yfrne.2010.10.001
78
FillingimRBKingCDRibeiro-DasilvaMCRahim-WilliamsBRileyJLIII. Sex, gender, and pain: a review of recent clinical and experimental findings. J Pain (2009) 10(5):447–85.10.1016/j.jpain.2008.12.001
79
Yalinay DikmenPIlgaz AydinlarEKarlikayaG. Pain levels of examined muscles and gender differences in pain during electromyography. Agri (2015) 27(2):79–82.10.5505/agri.2015.32154
80
DefrinRShrammLEliI. Gender role expectations of pain is associated with pain tolerance limit but not with pain threshold. Pain (2009) 145(1–2):230–6.10.1016/j.pain.2009.06.028
81
LesinMDomazet BugarinJPuljakL. Factors associated with postoperative pain and analgesic consumption in ophthalmic surgery: a systematic review. Surv Ophthalmol (2015) 60(3):196–203.10.1016/j.survophthal.2014.10.003
82
GuptaPDJoharKSrNagpalKVasavadaAR. Sex hormone receptors in the human eye. Surv Ophthalmol (2005) 50(3):274–84.10.1016/j.survophthal.2005.02.005
83
StromqvistFStromqvistBJonssonBKarlssonMK. Gender differences in patients scheduled for lumbar disc herniation surgery: a National Register Study including 15,631 operations. Eur Spine J (2016) 25(1):162–7.10.1007/s00586-015-4052-5
84
MansfieldKESimJJordanJLJordanKP. A systematic review and meta-analysis of the prevalence of chronic widespread pain in the general population. Pain (2016) 157(1):55–64.10.1097/j.pain.0000000000000314
85
SinglaNKDesjardinsPJChangPD. A comparison of the clinical and experimental characteristics of four acute surgical pain models: dental extraction, bunionectomy, joint replacement, and soft tissue surgery. Pain (2014) 155(3):441–56.10.1016/j.pain.2013.09.002
86
HurleyRWAdamsMC. Sex, gender, and pain: an overview of a complex field. Anesth Analg (2008) 107(1):309–17.10.1213/01.ane.0b013e31816ba437
87
KestBHopkinsEPalmeseCAAdlerMMogilJS. Genetic variation in morphine analgesic tolerance: a survey of 11 inbred mouse strains. Pharmacol Biochem Behav (2002) 73(4):821–8.10.1016/S0091-3057(02)00908-5
88
MuraEGovoniSRacchiMCarossaVRanzaniGNAllegriMet alConsequences of the 118A>G polymorphism in the OPRM1 gene: translation from bench to bedside?J Pain Res (2013) 6:331–53.10.2147/JPR.S42040
89
PasternakGWPanYX. Mu opioids and their receptors: evolution of a concept. Pharmacol Rev (2013) 65(4):1257–317.10.1124/pr.112.007138
90
MacGregorEA. Migraine management during menstruation and menopause. Continuum (Minneap Minn) (2015) 21(4 Headache):990–1003.10.1212/CON.0000000000000196
91
Eikermann-HaerterKDilekozEKudoCSavitzSIWaeberCBaumMJet alGenetic and hormonal factors modulate spreading depression and transient hemiparesis in mouse models of familial hemiplegic migraine type 1. J Clin Invest (2009) 119(1):99–109.10.1172/JCI36059
92
Eikermann-HaerterKBaumMJFerrariMDvan den MaagdenbergAMMoskowitzMAAyataC. Androgenic suppression of spreading depression in familial hemiplegic migraine type 1 mutant mice. Ann Neurol (2009) 66(4):564–8.10.1002/ana.21779
93
BorsookDErpeldingNLebelALinnmanCVeggebergRGrantPEet alSex and the migraine brain. Neurobiol Dis (2014) 68:200–14.10.1016/j.nbd.2014.03.008
94
GrecoRTassorelliCMangioneASSmeraldiAAllenaMSandriniGet alEffect of sex and estrogens on neuronal activation in an animal model of migraine. Headache (2013) 53(2):288–96.10.1111/j.1526-4610.2012.02249.x
95
SachsMPapeHCSpeckmannEJGorjiA. The effect of estrogen and progesterone on spreading depression in rat neocortical tissues. Neurobiol Dis (2007) 25(1):27–34.10.1016/j.nbd.2006.08.013
96
ChauvelVVamosEPardutzAVecseiLSchoenenJMultonS. Effect of systemic kynurenine on cortical spreading depression and its modulation by sex hormones in rat. Exp Neurol (2012) 236(2):207–14.10.1016/j.expneurol.2012.05.002
97
SrivastavaDPWoolfreyKMPenzesP. Insights into rapid modulation of neuroplasticity by brain estrogens. Pharmacol Rev (2013) 65(4):1318–50.10.1124/pr.111.005272
98
SorgeREMapplebeckJCRosenSBeggsSTavesSAlexanderJKet alDifferent immune cells mediate mechanical pain hypersensitivity in male and female mice. Nat Neurosci (2015) 18(8):1081–3.10.1038/nn.4053
99
SorgeREMartinLJIsbesterKASotocinalSGRosenSTuttleAHet alOlfactory exposure to males, including men, causes stress and related analgesia in rodents. Nat Methods (2014) 11(6):629–32.10.1038/nmeth.2935
100
DiamondSBigalMESilbersteinSLoderEReedMLiptonRB. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache (2007) 47(3):355–63.
101
BrusaPAllaisGRolandoSBarattaFGiacconeMBussoneGet alMigraine attacks in the pharmacy: a gender subanalysis on treatment preferences. Neurol Sci (2015) 36(Suppl 1):93–5.10.1007/s10072-015-2156-7
102
DodickDWLiptonRBGoadsbyPJTfelt-HansenPFerrariMDDienerHCet alPredictors of migraine headache recurrence: a pooled analysis from the eletriptan database. Headache (2008) 48(2):184–93.10.1111/j.1526-4610.2007.00868.x
103
BurchRCLoderSLoderESmithermanTA. The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies. Headache (2015) 55(1):21–34.10.1111/head.12482
104
AuroraSKKulthiaABarrodalePM. Mechanism of chronic migraine. Curr Pain Headache Rep (2011) 15(1):57–63.10.1007/s11916-010-0165-z
105
CiceroTJNockBMeyerER. Sex-related differences in morphine’s antinociceptive activity: relationship to serum and brain morphine concentrations. J Pharmacol Exp Ther (1997) 282(2):939–44.
106
ZubietaJKSmithYRBuellerJAXuYKilbournMRJewettDMet almu-opioid receptor-mediated antinociceptive responses differ in men and women. J Neurosci (2002) 22(12):5100–7.
107
LoydDRMurphyAZ. The neuroanatomy of sexual dimorphism in opioid analgesia. Exp Neurol (2014) 259:57–63.10.1016/j.expneurol.2014.04.004
108
PolyakovaMStukeKSchuembergKMuellerKSchoenknechtPSchroeterML. BDNF as a biomarker for successful treatment of mood disorders: a systematic & quantitative meta-analysis. J Affect Disord (2015) 174:432–40.10.1016/j.jad.2014.11.044
109
LewisSSHutchinsonMRFrickMMZhangYMaierSFSammakiaTet alSelect steroid hormone glucuronide metabolites can cause toll-like receptor 4 activation and enhanced pain. Brain Behav Immun (2015) 44:128–36.10.1016/j.bbi.2014.09.004
110
Le MerrerJBeckerJABefortKKiefferBL. Reward processing by the opioid system in the brain. Physiol Rev (2009) 89(4):1379–412.10.1152/physrev.00005.2009
111
KrzanowskaEKBodnarRJ. Morphine antinociception elicited from the ventrolateral periaqueductal gray is sensitive to sex and gonadectomy differences in rats. Brain Res (1999) 821(1):224–30.10.1016/S0006-8993(98)01364-X
112
MicevychPERissmanEFGustafssonJASinchakK. Estrogen receptor-alpha is required for estrogen-induced mu-opioid receptor internalization. J Neurosci Res (2003) 71(6):802–10.10.1002/jnr.10526
113
MikaJOsikowiczMMakuchWPrzewlockaB. Minocycline and pentoxifylline attenuate allodynia and hyperalgesia and potentiate the effects of morphine in rat and mouse models of neuropathic pain. Eur J Pharmacol (2007) 560(2–3):142–9.10.1016/j.ejphar.2007.01.013
114
HutchinsonMRNorthcuttALChaoLWKearneyJJZhangYBerkelhammerDLet alMinocycline suppresses morphine-induced respiratory depression, suppresses morphine-induced reward, and enhances systemic morphine-induced analgesia. Brain Behav Immun (2008) 22(8):1248–56.10.1016/j.bbi.2008.07.008
115
CuiYLiaoXXLiuWGuoRXWuZZZhaoCMet alA novel role of minocycline: attenuating morphine antinociceptive tolerance by inhibition of p38 MAPK in the activated spinal microglia. Brain Behav Immun (2008) 22(1):114–23.10.1016/j.bbi.2007.07.014
116
LewisSSHutchinsonMRRezvaniNLoramLCZhangYMaierSFet alEvidence that intrathecal morphine-3-glucuronide may cause pain enhancement via toll-like receptor 4/MD-2 and interleukin-1beta. Neuroscience (2010) 165(2):569–83.10.1016/j.neuroscience.2009.10.011
117
SorgeRELaCroix-FralishMLTuttleAHSotocinalSGAustinJSRitchieJet alSpinal cord Toll-like receptor 4 mediates inflammatory and neuropathic hypersensitivity in male but not female mice. J Neurosci (2011) 31(43):15450–4.10.1523/JNEUROSCI.3859-11.2011
118
Lambracht-HallMDimitriadouVTheoharidesTC. Migration of mast cells in the developing rat brain. Brain Res Dev Brain Res (1990) 56(2):151–9.10.1016/0165-3806(90)90077-C
119
TheoharidesTCSinghLKBoucherWPangXLetourneauRWebsterEet alCorticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its proinflammatory effects. Endocrinology (1998) 139(1):403–13.10.1210/en.139.1.403
120
SilvermanAJSutherlandAKWilhelmMSilverR. Mast cells migrate from blood to brain. J Neurosci (2000) 20(1):401–8.
121
Van NassauwLAdriaensenDTimmermansJP. The bidirectional communication between neurons and mast cells within the gastrointestinal tract. Auton Neurosci (2007) 133(1):91–103.10.1016/j.autneu.2006.10.003
122
ForsythePBienenstockJ. The mast cell-nerve functional unit: a key component of physiologic and pathophysiologic responses. Chem Immunol Allergy (2012) 98:196–221.10.1159/000336523
123
SchemannMCamilleriM. Functions and imaging of mast cell and neural axis of the gut. Gastroenterology (2013) 144(4):698–704e4.10.1053/j.gastro.2013.01.040
124
SteadRHDixonMFBramwellNHRiddellRHBienenstockJ. Mast cells are closely apposed to nerves in the human gastrointestinal mucosa. Gastroenterology (1989) 97(3):575–85.
125
GalliSJ. New concepts about the mast cell. N Engl J Med (1993) 328(4):257–65.10.1056/NEJM199301283280408
126
KrabbeAAOlesenJ. Headache provocation by continuous intravenous infusion of histamine. Clinical results and receptor mechanisms. Pain (1980) 8(2):253–9.10.1016/0304-3959(88)90012-7
127
LaMarteFPMerchantJACasaleTB. Acute systemic reactions to carbonless copy paper associated with histamine release. JAMA (1988) 260(2):242–3.10.1001/jama.1988.03410020108039
128
CutzEChanWTrackNSGothASaidSI. Release of vasoactive intestinal polypeptide in mast cells by histamine liberators. Nature (1978) 275(5681):661–2.10.1038/275661a0
129
MannaioniPFMasiniEPistelliASalveminiDVaneJR. Mast cells as a source of superoxide anions and nitric oxide-like factor: relevance to histamine release. Int J Tissue React (1991) 13(6):271–8.
130
TheoharidesTCSpanosCPangXAlferesLLigrisKLetourneauRet alStress-induced intracranial mast cell degranulation: a corticotropin-releasing hormone-mediated effect. Endocrinology (1995) 136(12):5745–50.10.1210/en.136.12.5745
131
AlhelalMAPalaskaIPanagiotidouSLetourneauRTheoharidesTC. Trigeminal nerve stimulation triggers oral mast cell activation and vascular permeability. Ann Allergy Asthma Immunol (2014) 112(1):40–5.10.1016/j.anai.2013.10.011
132
AkbarAYiangouYFacerPWaltersJRAnandPGhoshS. Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut (2008) 57(7):923–9.10.1136/gut.2007.138982
133
ZhangXCStrassmanAMBursteinRLevyD. Sensitization and activation of intracranial meningeal nociceptors by mast cell mediators. J Pharmacol Exp Ther (2007) 322(2):806–12.10.1124/jpet.107.123745
134
ItoAJippoTWakayamaTMoriiEKomaYOndaHet alSgIGSF: a new mast-cell adhesion molecule used for attachment to fibroblasts and transcriptionally regulated by MITF. Blood (2003) 101(7):2601–8.10.1182/blood-2002-07-2265
135
BiedererTSaraYMozhayevaMAtasoyDLiuXKavalaliETet alSynCAM, a synaptic adhesion molecule that drives synapse assembly. Science (2002) 297(5586):1525–31.10.1126/science.1072356
136
ItoAOonumaJ. Direct interaction between nerves and mast cells mediated by the SgIGSF/SynCAM adhesion molecule. J Pharmacol Sci (2006) 102(1):1–5.10.1254/jphs.CPJ06014X
137
HanSKDongXHwangJIZylkaMJAndersonDJSimonMI. Orphan G protein-coupled receptors MrgA1 and MrgC11 are distinctively activated by RF-amide-related peptides through the Galpha q/11 pathway. Proc Natl Acad Sci U S A (2002) 99(23):14740–5.10.1073/pnas.192565799
138
FevrierBRaposoG. Exosomes: endosomal-derived vesicles shipping extracellular messages. Curr Opin Cell Biol (2004) 16(4):415–21.10.1016/j.ceb.2004.06.003
139
ValadiHEkstromKBossiosASjostrandMLeeJJLotvallJO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol (2007) 9(6):654–9.10.1038/ncb1596
140
van NielGPorto-CarreiroISimoesSRaposoG. Exosomes: a common pathway for a specialized function. J Biochem (2006) 140(1):13–21.10.1093/jb/mvj128
141
SherringtonCS. Observations on the scratch-reflex in the spinal dog. J Physiol (1906) 34(1–2):1–50.10.1113/jphysiol.1906.sp001139
142
WoodJD. Enteric neuroimmunophysiology and pathophysiology. Gastroenterology (2004) 127(2):635–57.10.1053/j.gastro.2004.02.017
143
BlackshawLABrookesSJGrundyDSchemannM. Sensory transmission in the gastrointestinal tract. Neurogastroenterol Motil (2007) 19(1 Suppl):1–19.10.1111/j.1365-2982.2006.00871.x
144
WoodJD. Nonruminant nutrition symposium: neurogastroenterology and food allergies. J Anim Sci (2012) 90(4):1213–23.10.2527/jas.2011-4787
145
MaweGM. Tachykinins as mediators of slow EPSPs in guinea-pig gall-bladder ganglia: involvement of neurokinin-3 receptors. J Physiol (1995) 485(Pt 2):513–24.10.1113/jphysiol.1995.sp020747
146
BalukP. Neurogenic inflammation in skin and airways. J Investig Dermatol Symp Proc (1997) 2(1):76–81.10.1038/jidsymp.1997.15
147
XanthosDNGadererSDrdlaRNuroEAbramovaAEllmeierWet alCentral nervous system mast cells in peripheral inflammatory nociception. Mol Pain (2011) 7:42.10.1186/1744-8069-7-42
148
LevyDKainzVBursteinRStrassmanAM. Mast cell degranulation distinctly activates trigemino-cervical and lumbosacral pain pathways and elicits widespread tactile pain hypersensitivity. Brain Behav Immun (2012) 26(2):311–7.10.1016/j.bbi.2011.09.016
149
KodaHMizumuraK. Sensitization to mechanical stimulation by inflammatory mediators and by mild burn in canine visceral nociceptors in vitro. J Neurophysiol (2002) 87(4):2043–51.
150
Leal-BerumenIConlonPMarshallJS. IL-6 production by rat peritoneal mast cells is not necessarily preceded by histamine release and can be induced by bacterial lipopolysaccharide. J Immunol (1994) 152(11):5468–76.
151
CaterinaMJSchumacherMATominagaMRosenTALevineJDJuliusD. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature (1997) 389(6653):816–24.10.1038/39807
152
JordtSEBautistaDMChuangHHMcKemyDDZygmuntPMHogestattEDet alMustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1. Nature (2004) 427(6971):260–5.10.1038/nature02282
153
DuxMRostaJSanthaPJancsoG. Involvement of capsaicin-sensitive afferent nerves in the proteinase-activated receptor 2-mediated vasodilatation in the rat dura mater. Neuroscience (2009) 161(3):887–94.10.1016/j.neuroscience.2009.04.010
154
EvansMSChengXJeffryJADisneyKEPremkumarLS. Sumatriptan inhibits TRPV1 channels in trigeminal neurons. Headache (2012) 52(5):773–84.10.1111/j.1526-4610.2011.02053.x
155
DuxMSanthaPJancsoG. The role of chemosensitive afferent nerves and TRP ion channels in the pathomechanism of headaches. Pflugers Arch (2012) 464(3):239–48.10.1007/s00424-012-1142-7
156
EspositoPGheorgheDKandereKPangXConnollyRJacobsonSet alAcute stress increases permeability of the blood-brain-barrier through activation of brain mast cells. Brain Res (2001) 888(1):117–27.10.1016/S0006-8993(00)03026-2
157
AlstadhaugKB. Histamine in migraine and brain. Headache (2014) 54(2):246–59.10.1111/head.12293
158
JenningsSRussellNJenningsBSleeVSterlingLCastellsMet alThe Mastocytosis Society survey on mast cell disorders: patient experiences and perceptions. J Allergy Clin Immunol Pract (2014) 2(1):70–6.10.1016/j.jaip.2013.09.004
159
MouraDSSultanSGeorgin-LavialleSBareteSLortholaryOGaillardRet alEvidence for cognitive impairment in mastocytosis: prevalence, features and correlations to depression. PLoS One (2012) 7(6):e39468.10.1371/journal.pone.0039468
160
ZierauOZenclussenACJensenF. Role of female sex hormones, estradiol and progesterone, in mast cell behavior. Front Immunol (2012) 3:169.10.3389/fimmu.2012.00169
161
HammesSRDavisPJ. Overlapping nongenomic and genomic actions of thyroid hormone and steroids. Best Pract Res Clin Endocrinol Metab (2015) 29(4):581–93.10.1016/j.beem.2015.04.001
162
ChenWBeckISchoberWBrockowKEffnerRButersJTet alHuman mast cells express androgen receptors but treatment with testosterone exerts no influence on IgE-independent mast cell degranulation elicited by neuromuscular blocking agents. Exp Dermatol (2010) 19(3):302–4.10.1111/j.1600-0625.2009.00969.x
163
BoesTLevyD. Influence of sex, estrous cycle, and estrogen on intracranial dural mast cells. Cephalalgia (2012) 32(12):924–31.10.1177/0333102412454947
164
BondsRSMidoro-HoriutiT. Estrogen effects in allergy and asthma. Curr Opin Allergy Clin Immunol (2013) 13(1):92–9.10.1097/ACI.0b013e32835a6dd6
165
UemuraYLiuTYNaritaYSuzukiMMatsushitaS. 17 Beta-estradiol (E2) plus tumor necrosis factor-alpha induces a distorted maturation of human monocyte-derived dendritic cells and promotes their capacity to initiate T-helper 2 responses. Hum Immunol (2008) 69(3):149–57.10.1016/j.humimm.2008.01.017
166
GuoHLiuTUemuraYJiaoSWangDLinZet alBisphenol A in combination with TNF-alpha selectively induces Th2 cell-promoting dendritic cells in vitro with an estrogen-like activity. Cell Mol Immunol (2010) 7(3):227–34.10.1038/cmi.2010.14
167
NaritaSGoldblumRMWatsonCSBrooksEGEstesDMCurranEMet alEnvironmental estrogens induce mast cell degranulation and enhance IgE-mediated release of allergic mediators. Environ Health Perspect (2007) 115(1):48–52.10.1289/ehp.9378
168
KennedyRHPelletierJHTupperEJHutchinsonLMGosseJA. Estrogen mimetic 4-tert-octylphenol enhances IgE-mediated degranulation of RBL-2H3 mast cells. J Toxicol Environ Health A (2012) 75(24):1451–5.10.1080/15287394.2012.722184
169
VermeerLMGregoryEWinterMKMcCarsonKEBermanNE. Exposure to bisphenol A exacerbates migraine-like behaviors in a multibehavior model of rat migraine. Toxicol Sci (2014) 137(2):416–27.10.1093/toxsci/kft245
170
RozenTDSwansonJWStangPEMcDonnellSKRoccaWA. Increasing incidence of medically recognized migraine headache in a United States population. Neurology (1999) 53(7):1468–73.10.1212/WNL.53.7.1468
171
SzyszkowiczMStiebDMRoweBH. Air pollution and daily ED visits for migraine and headache in Edmonton, Canada. Am J Emerg Med (2009) 27(4):391–6.10.1016/j.ajem.2008.03.013
172
KoushaTValacchiG. The air quality health index and emergency department visits for urticaria in Windsor, Canada. J Toxicol Environ Health A (2015) 78(8):524–33.10.1080/15287394.2014.991053
173
SomponpunSJ. Neuroendocrine regulation of fluid and electrolyte balance by ovarian steroids: contributions from central oestrogen receptors. J Neuroendocrinol (2007) 19(10):809–18.10.1111/j.1365-2826.2007.01587.x
174
SladekCDSomponpunSJ. Estrogen receptors: their roles in regulation of vasopressin release for maintenance of fluid and electrolyte homeostasis. Front Neuroendocrinol (2008) 29(1):114–27.10.1016/j.yfrne.2007.08.005
175
SomponpunSJSladekCD. Osmotic regulation of estrogen receptor-beta in rat vasopressin and oxytocin neurons. J Neurosci (2003) 23(10):4261–9.
176
von Bohlen und HalbachOAlbrechtD. The CNS renin-angiotensin system. Cell Tissue Res (2006) 326(2):599–616.10.1007/s00441-006-0190-8
177
WrightJWReichertJRDavisCJHardingJW. Neural plasticity and the brain renin-angiotensin system. Neurosci Biobehav Rev (2002) 26(5):529–52.10.1016/S0149-7634(02)00019-2
178
HilliardLMMirabitoKMDentonKM. Unmasking the potential of the angiotensin AT2 receptor as a therapeutic target in hypertension in men and women: what we know and what we still need to find out. Clin Exp Pharmacol Physiol (2013) 40(8):542–50.10.1111/1440-1681.12067
179
RipaPOrnelloRPistoiaFCaroleiASaccoS. The renin-angiotensin system: a possible contributor to migraine pathogenesis and prophylaxis. Expert Rev Neurother (2014) 14(9):1043–55.10.1586/14737175.2014.946408
180
FusayasuEKowaHTakeshimaTNakasoKNakashimaK. Increased plasma substance P and CGRP levels, and high ACE activity in migraineurs during headache-free periods. Pain (2007) 128(3):209–14.10.1016/j.pain.2006.09.017
181
SchurksMRistPMKurthT. Sex hormone receptor gene polymorphisms and migraine: a systematic review and meta-analysis. Cephalalgia (2010) 30(11):1306–28.10.1177/0333102410364155
182
SchurksMRistPMKurthT. MTHFR 677C>T and ACE D/I polymorphisms in migraine: a systematic review and meta-analysis. Headache (2010) 50(4):588–99.10.1111/j.1526-4610.2009.01570.x
183
HaradaNShimozawaNOkajimaK. AT(1) receptor blockers increase insulin-like growth factor-I production by stimulating sensory neurons in spontaneously hypertensive rats. Transl Res (2009) 154(3):142–52.10.1016/j.trsl.2009.06.004
184
WilsonACClementeLLiuTBowenRLMeethalSVAtwoodCS. Reproductive hormones regulate the selective permeability of the blood-brain barrier. Biochim Biophys Acta (2008) 1782(6):401–7.10.1016/j.bbadis.2008.02.011
185
HawkinsBTDavisTP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev (2005) 57(2):173–85.10.1124/pr.57.2.4
186
RosenbergGA. Neurological diseases in relation to the blood-brain barrier. J Cereb Blood Flow Metab (2012) 32(7):1139–51.10.1038/jcbfm.2011.197
187
WolffHG. Wolff’s Headache and Other Head Pain. 3d ed. (Vol. xiv). New York: Oxford University Press (1972). 688 p.
188
LevyDBursteinR. The vascular theory of migraine: leave it or love it?Ann Neurol (2011) 69(4):600–1.10.1002/ana.22422
189
GoadsbyPJ. The vascular theory of migraine – a great story wrecked by the facts. Brain (2009) 132(Pt 1):6–7.10.1093/brain/awn321
190
ShevelE. The extracranial vascular theory of migraine – a great story confirmed by the facts. Headache (2011) 51(3):409–17.10.1111/j.1526-4610.2011.01844.x
191
KoinaMEBaxterLAdamsonSJArfusoFHuPMadiganMCet alEvidence for lymphatics in the developing and adult human choroid. Invest Ophthalmol Vis Sci (2015) 56(2):1310–27.10.1167/iovs.14-15705
192
LouveauASmirnovIKeyesTJEcclesJDRouhaniSJPeskeJDet alStructural and functional features of central nervous system lymphatic vessels. Nature (2015) 523(7560):337–41.10.1038/nature14432
193
RaduBMBramantiPOsculatiFFlontaMLRaduMBertiniGet alNeurovascular unit in chronic pain. Mediators Inflamm (2013) 2013:648268.10.1155/2013/648268
194
DreierJPJurkat-RottKPetzoldGCTomkinsOKlingebielRKoppUAet alOpening of the blood-brain barrier preceding cortical edema in a severe attack of FHM type II. Neurology (2005) 64(12):2145–7.10.1212/01.WNL.0000176298.63840.99
195
Gursoy-OzdemirYQiuJMatsuokaNBolayHBermpohlDJinHet alCortical spreading depression activates and upregulates MMP-9. J Clin Invest (2004) 113(10):1447–55.10.1172/JCI200421227
196
PotenzieriCMeekerSUndemBJ. Activation of mouse bronchopulmonary C-fibres by serotonin and allergen-ovalbumin challenge. J Physiol (2012) 590(Pt 21):5449–59.10.1113/jphysiol.2012.237115
197
ColdwellJRPhillisBDSutherlandKHowarthGSBlackshawLA. Increased responsiveness of rat colonic splanchnic afferents to 5-HT after inflammation and recovery. J Physiol (2007) 579(Pt 1):203–13.10.1113/jphysiol.2006.123158
198
Martins-OliveiraAGoncalvesFMSpecialiJGFontanaVIzidoro-ToledoTCBeloVAet alSpecific matrix metalloproteinase 9 (MMP-9) haplotype affect the circulating MMP-9 levels in women with migraine. J Neuroimmunol (2012) 252(1–2):89–94.10.1016/j.jneuroim.2012.07.016
199
GuptaVKCSD. BBB and MMP-9 elevations: animal experiments versus clinical phenomena in migraine. Expert Rev Neurother (2009) 9(11):1595–614.10.1586/ern.09.103
200
FerrariATiraferriINeriLSternieriE. Why pharmacokinetic differences among oral triptans have little clinical importance: a comment. J Headache Pain (2011) 12(1):5–12.10.1007/s10194-010-0258-4
201
VermeerschSGGFrederiksPMaassen VandenBrinkAde HoonJ. Capsaicin-induced CGRP-mediated vasodilatation of the human skin: influence of gender, female hormones and migraine. J Headache Pain (2013) 14(Suppl 1):124.10.1186/1129-2377-14-S1-P124
202
LeHTfelt-HansenPRussellMBSkyttheAKyvikKOOlesenJ. Co-morbidity of migraine with somatic disease in a large population-based study. Cephalalgia (2011) 31(1):43–64.10.1177/0333102410373159
203
BangasserDAZhangXGarachhVHanhauserEValentinoRJ. Sexual dimorphism in locus coeruleus dendritic morphology: a structural basis for sex differences in emotional arousal. Physiol Behav (2011) 103(3–4):342–51.10.1016/j.physbeh.2011.02.037
204
TedeschiGRussoAConteFLauraMTessitoreA. Vestibular migraine pathophysiology: insights from structural and functional neuroimaging. Neurol Sci (2015) 36(Suppl 1):37–40.10.1007/s10072-015-2161-x
205
BernatskySPineauCALeeJLClarkeAE. Headache, Raynaud’s syndrome and serotonin receptor agonists in systemic lupus erythematosus. Lupus (2006) 15(10):671–4.10.1177/0961203306069997
206
D’AmicoFSkarmoutsouEMazzarinoMC. The sex bias in systemic sclerosis: on the possible mechanisms underlying the female disease preponderance. Clin Rev Allergy Immunol (2014) 47(3):334–43.10.1007/s12016-013-8392-9
207
BaumgartnerCBlumMRRodondiN. Subclinical hypothyroidism: summary of evidence in 2014. Swiss Med Wkly (2014) 144:w14058.10.4414/smw.2014.14058
208
Yacoub WasefSZ. Gender differences in systemic lupus erythematosus. Gend Med (2004) 1(1):12–7.10.1016/S1550-8579(04)80006-8
209
CapozziAScambiaGPontecorviALelloS. Hyperprolactinemia: pathophysiology and therapeutic approach. Gynecol Endocrinol (2015) 31(7):506–10.10.3109/09513590.2015.1017810
210
KallestrupMMKaschHOsterbyTNielsenEJensenTSJorgensenJO. Prolactinoma-associated headache and dopamine agonist treatment. Cephalalgia (2013) 34(7):493–502.10.1177/0333102413515343
211
BerrySHElliottMNSuttorpMBogartLMStotoMAEggersPet alPrevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. J Urol (2011) 186(2):540–4.10.1016/j.juro.2011.03.132
212
SuskindAMBerrySHEwingBAElliottMNSuttorpMJClemensJQ. The prevalence and overlap of interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome in men: results of the RAND Interstitial Cystitis Epidemiology male study. J Urol (2013) 189(1):141–5.10.1016/j.juro.2012.08.088
213
ClauwDJSchmidtMRadulovicDSingerAKatzPBresetteJ. The relationship between fibromyalgia and interstitial cystitis. J Psychiatr Res (1997) 31(1):125–31.10.1016/S0022-3956(96)00051-9
214
NoviJMJeronisSSrinivasSSrinivasanRMorganMAAryaLA. Risk of irritable bowel syndrome and depression in women with interstitial cystitis: a case-control study. J Urol (2005) 174(3):937–40.10.1097/01.ju.0000169258.31345.5d
215
MayerEAGuptaAKilpatrickLAHongJY. Imaging brain mechanisms in chronic visceral pain. Pain (2015) 156(Suppl 1):S50–63.10.1097/j.pain.0000000000000106
216
DeBerryJJRobbinsMTNessTJ. The amygdala central nucleus is required for acute stress-induced bladder hyperalgesia in a rat visceral pain model. Brain Res (2015) 1606:77–85.10.1016/j.brainres.2015.01.008
217
TheoharidesTCSantGRel-MansouryMLetourneauRUcciAAJrMearesEMJr. Activation of bladder mast cells in interstitial cystitis: a light and electron microscopic study. J Urol (1995) 153(3 Pt 1):629–36.10.1016/S0022-5347(01)67669-9
218
AnderssonKE. Purinergic signalling in the urinary bladder. Auton Neurosci (2015) 191:78–81.10.1016/j.autneu.2015.04.012
219
BirderLAWolf-JohnstonASChibMKBuffingtonCARoppoloJRHanna-MitchellAT. Beyond neurons: involvement of urothelial and glial cells in bladder function. Neurourol Urodyn (2010) 29(1):88–96.10.1002/nau.20747
220
De MarcoRLocatelliFCerveriIBugianiMMarinoniAGiammancoGet alIncidence and remission of asthma: a retrospective study on the natural history of asthma in Italy. J Allergy Clin Immunol (2002) 110(2):228–35.10.1067/mai.2002.125600
221
SchatzMCamargoCAJr. The relationship of sex to asthma prevalence, health care utilization, and medications in a large managed care organization. Ann Allergy Asthma Immunol (2003) 91(6):553–8.10.1016/S1081-1206(10)61533-5
222
ManninoDMHomaDMAkinbamiLJMoormanJEGwynnCReddSC. Surveillance for asthma – United States, 1980-1999. MMWR Surveill Summ (2002) 51(1):1–13.
223
VriezeAPostmaDSKerstjensHA. Perimenstrual asthma: a syndrome without known cause or cure. J Allergy Clin Immunol (2003) 112(2):271–82.10.1067/mai.2003.1676
224
Ligeiro de OliveiraAPOliveira-FilhoRMda SilvaZLBorelliPTavares de LimaW. Regulation of allergic lung inflammation in rats: interaction between estradiol and corticosterone. Neuroimmunomodulation (2004) 11(1):20–7.10.1159/000072965
225
BarbaraGWangBStanghelliniVde GiorgioRCremonCDi NardoGet alMast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology (2007) 132(1):26–37.10.1053/j.gastro.2006.11.039
226
OmoriYAndohTShirakawaHIshidaHHachigaTKuraishiY. Itch-related responses of dorsal horn neurons to cutaneous allergic stimulation in mice. Neuroreport (2009) 20(5):478–81.10.1097/WNR.0b013e3283293725
227
JiangWKreisMEEastwoodCKirkupAJHumphreyPPGrundyD. 5-HT(3) and histamine H(1) receptors mediate afferent nerve sensitivity to intestinal anaphylaxis in rats. Gastroenterology (2000) 119(5):1267–75.10.1053/gast.2000.19461
228
GuQLimMEGleichGJLeeLY. Mechanisms of eosinophil major basic protein-induced hyperexcitability of vagal pulmonary chemosensitive neurons. Am J Physiol Lung Cell Mol Physiol (2009) 296(3):L453–61.10.1152/ajplung.90467.2008
229
UndemBJTaylor-ClarkT. Mechanisms underlying the neuronal-based symptoms of allergy. J Allergy Clin Immunol (2014) 133(6):1521–34.10.1016/j.jaci.2013.11.027
230
BrierleySMLindenDR. Neuroplasticity and dysfunction after gastrointestinal inflammation. Nat Rev Gastroenterol Hepatol (2014) 11(10):611–27.10.1038/nrgastro.2014.103
231
DimitrovaAKUngaroRCLebwohlBLewisSKTennysonCAGreenMWet alPrevalence of migraine in patients with celiac disease and inflammatory bowel disease. Headache (2013) 53(2):344–55.10.1111/j.1526-4610.2012.02260.x
232
MaweGM. Colitis-induced neuroplasticity disrupts motility in the inflamed and post-inflamed colon. J Clin Invest (2015) 125(3):949–55.10.1172/JCI76306
233
CervellinGLippiG. Abdominal migraine in the differential diagnosis of acute abdominal pain. Am J Emerg Med (2015) 33(6):e3–5.10.1016/j.ajem.2014.12.066
234
WeigandLAMyersACMeekerSUndemBJ. Mast cell-cholinergic nerve interaction in mouse airways. J Physiol (2009) 587(Pt 13):3355–62.10.1113/jphysiol.2009.173054
235
CyphertJMKovarovaMAllenICHartneyJMMurphyDLWessJet alCooperation between mast cells and neurons is essential for antigen-mediated bronchoconstriction. J Immunol (2009) 182(12):7430–9.10.4049/jimmunol.0900039
236
BischoffSCGebhardtT. Role of mast cells and eosinophils in neuroimmune interactions regulating mucosal inflammation in inflammatory bowel disease. Adv Exp Med Biol (2006) 579:177–208.10.1007/0-387-33778-4_12
237
CremonCCariniGWangBVasinaVCogliandroRFDe GiorgioRet alIntestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am J Gastroenterol (2011) 106(7):1290–8.10.1038/ajg.2011.86
238
BarbaraGStanghelliniVDe GiorgioRCremonCCottrellGSSantiniDet alActivated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology (2004) 126(3):693–702.10.1053/j.gastro.2003.11.055
239
BuhnerSLiQVignaliSBarbaraGDe GiorgioRStanghelliniVet alActivation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology (2009) 137(4):1425–34.10.1053/j.gastro.2009.07.005
240
Valdez-MoralesEEOveringtonJGuerrero-AlbaROchoa-CortesFIbeakanmaCOSpreadburyIet alSensitization of peripheral sensory nerves by mediators from colonic biopsies of diarrhea-predominant irritable bowel syndrome patients: a role for PAR2. Am J Gastroenterol (2013) 108(10):1634–43.10.1038/ajg.2013.241
241
DothelGBarbaroMRBoudinHVasinaVCremonCGarganoLet alNerve fiber outgrowth is increased in the intestinal mucosa of patients with irritable bowel syndrome. Gastroenterology (2015) 148(5):1002.e–11.e.10.1053/j.gastro.2015.01.042
242
ParkmanHP. Migraine and gastroparesis from a gastroenterologist’s perspective. Headache (2013) 53(Suppl 1):4–10.10.1111/head.12112
243
BreinbjergALangeARittigSKamperisK. Inappropriate arginine vasopressin levels and hyponatremia associated with cyclic vomiting syndrome. Case Rep Gastroenterol (2015) 9(1):20–4.10.1159/000373884
244
GelfandAAGoadsbyPJAllenIE. The relationship between migraine and infant colic: a systematic review and meta-analysis. Cephalalgia (2015) 35(1):63–72.10.1177/0333102414534326
245
GelfandAAThomasKCGoadsbyPJ. Before the headache: infant colic as an early life expression of migraine. Neurology (2012) 79(13):1392–6.10.1212/WNL.0b013e31826c1b7b
246
PerrotS. Osteoarthritis pain. Best Pract Res Clin Rheumatol (2015) 29(1):90–7.10.1016/j.berh.2015.04.017
247
BrzustewiczEBrylE. The role of cytokines in the pathogenesis of rheumatoid arthritis – Practical and potential application of cytokines as biomarkers and targets of personalized therapy. Cytokine (2015) 76(2):527–36.10.1016/j.cyto.2015.08.260
248
de Lange-BrokaarBJIoan-FacsinayAvan OschGJZuurmondAMSchoonesJToesREet alSynovial inflammation, immune cells and their cytokines in osteoarthritis: a review. Osteoarthritis Cartilage (2012) 20(12):1484–99.10.1016/j.joca.2012.08.027
249
PicernoVFerroFAdinolfiAValentiniETaniCAlunnoA. One year in review: the pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol (2015) 33(4):551–8.
250
de RooyDPZhernakovaATsonakaRWillemzeAKurreemanBATrynkaGet alA genetic variant in the region of MMP-9 is associated with serum levels and progression of joint damage in rheumatoid arthritis. Ann Rheum Dis (2014) 73(6):1163–9.10.1136/annrheumdis-2013-203375
251
KesslerRCDemlerOFrankRGOlfsonMPincusHAWaltersEEet alPrevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med (2005) 352(24):2515–23.10.1056/NEJMsa043266
252
BruceSEYonkersKAOttoMWEisenJLWeisbergRBPaganoMet alInfluence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry (2005) 162(6):1179–87.10.1176/appi.ajp.162.6.1179
253
KesslerRCFosterCLSaundersWBStangPE. Social consequences of psychiatric disorders, I: educational attainment. Am J Psychiatry (1995) 152(7):1026–32.10.1176/ajp.152.7.1026
254
KesslerRCMcGonagleKAZhaoSNelsonCBHughesMEshlemanSet alLifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry (1994) 51(1):8–19.10.1001/archpsyc.1994.03950010008002
255
SelyeH. Stress and disease. Science (1955) 122(3171):625–31.10.1126/science.122.3171.625
256
LucassenEAPiaggiPDsurneyJde JongeLZhaoXCMattinglyMSet alSleep extension improves neurocognitive functions in chronically sleep-deprived obese individuals. PLoS One (2014) 9(1):e84832.10.1371/journal.pone.0084832
257
CohenSJanicki-DevertsDDoyleWJMillerGEFrankERabinBSet alChronic stress, glucocorticoid receptor resistance, inflammation, and disease risk. Proc Natl Acad Sci U S A (2012) 109(16):5995–9.10.1073/pnas.1118355109
258
HamelskySWLiptonRB. Psychiatric comorbidity of migraine. Headache (2006) 46(9):1327–33.10.1111/j.1526-4610.2006.00576.x
259
PatelNVBigalMEKolodnerKBLeottaCLafataJELiptonRB. Prevalence and impact of migraine and probable migraine in a health plan. Neurology (2004) 63(8):1432–8.10.1212/01.WNL.0000142044.22226.54
260
RadatFSwendsenJ. Psychiatric comorbidity in migraine: a review. Cephalalgia (2005) 25(3):165–78.10.1111/j.1468-2982.2004.00839.x
261
BreslauNDavisGCAndreskiP. Migraine, psychiatric disorders, and suicide attempts: an epidemiologic study of young adults. Psychiatry Res (1991) 37(1):11–23.10.1016/0165-1781(91)90102-U
262
HungCILiuCYYangCHWangSJ. The impacts of migraine among outpatients with major depressive disorder at a two-year follow-up. PLoS One (2015) 10(5):e0128087.10.1371/journal.pone.0128087
263
LiptonRBStewartWFDiamondSDiamondMLReedM. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache (2001) 41(7):646–57.10.1046/j.1526-4610.2001.041007646.x
264
AntonaciFNappiGGalliFManzoniGCCalabresiPCostaA. Migraine and psychiatric comorbidity: a review of clinical findings. J Headache Pain (2011) 12(2):115–25.10.1007/s10194-010-0282-4
265
TietjenGEBrandesJLDigreKBBaggaleySMartinVRecoberAet alHigh prevalence of somatic symptoms and depression in women with disabling chronic headache. Neurology (2007) 68(2):134–40.10.1212/01.wnl.0000251195.55563.02
266
AshinaSSerranoDLiptonRBMaizelsMManackANTurkelCCet alDepression and risk of transformation of episodic to chronic migraine. J Headache Pain (2012) 13(8):615–24.10.1007/s10194-012-0479-9
267
GoldsteinILevyTGaliliDOvadiaHYirmiyaRRosenHet alInvolvement of Na(+), K(+)-ATPase and endogenous digitalis-like compounds in depressive disorders. Biol Psychiatry (2006) 60(5):491–9.10.1016/j.biopsych.2005.12.021
268
GoldsteinILaxEGispan-HermanIOvadiaHRosenHYadidGet alNeutralization of endogenous digitalis-like compounds alters catecholamines metabolism in the brain and elicits anti-depressive behavior. Eur Neuropsychopharmacol (2012) 22(1):72–9.10.1016/j.euroneuro.2011.05.007
269
BaskinSMSmithermanTA. Migraine and psychiatric disorders: comorbidities, mechanisms, and clinical applications. Neurol Sci (2009) 30(Suppl 1):S61–5.10.1007/s10072-009-0071-5
270
JuhaszGZsombokTLaszikAGondaXSotonyiPFaludiGet alAssociation analysis of 5-HTTLPR variants, 5-HT2a receptor gene 102T/C polymorphism and migraine. J Neurogenet (2003) 17(2–3):231–40.10.1080/714970154
271
MarziniakMMossnerRSchmittALeschKPSommerC. A functional serotonin transporter gene polymorphism is associated with migraine with aura. Neurology (2005) 64(1):157–9.10.1212/01.WNL.0000148597.52312.9E
272
HamelE. Serotonin and migraine: biology and clinical implications. Cephalalgia (2007) 27(11):1293–300.10.1111/j.1468-2982.2007.01476.x
273
SmithermanTAWaltersABMaizelsMPenzienDB. The use of antidepressants for headache prophylaxis. CNS Neurosci Ther (2011) 17(5):462–9.10.1111/j.1755-5949.2010.00170.x
274
MojaPLCusiCSterziRRCanepariC. Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches. Cochrane Database Syst Rev (2005) (3):CD002919.
275
PeckKRSmithermanTABaskinSM. Traditional and alternative treatments for depression: implications for migraine management. Headache (2015) 55(2):351–5.10.1111/head.12521
276
DamoiseauxVAProostJHJiawanVCMelgertBN. Sex differences in the pharmacokinetics of antidepressants: influence of female sex hormones and oral contraceptives. Clin Pharmacokinet (2014) 53(6):509–19.10.1007/s40262-014-0145-2
277
GillmanPK. Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): a review. Headache (2010) 50(2):264–72.10.1111/j.1526-4610.2009.01575.x
278
EvansRWTepperSJShapiroRESun-EdelsteinCTietjenGE. The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper. Headache (2010) 50(6):1089–99.10.1111/j.1526-4610.2010.01691.x
279
LipchikGLSmithermanTAPenzienDBHolroydKA. Basic principles and techniques of cognitive-behavioral therapies for comorbid psychiatric symptoms among headache patients. Headache (2006) 46(Suppl 3):S119–32.10.1111/j.1526-4610.2006.00563.x
280
CasucciGVillaniVFinocchiC. Therapeutic strategies in migraine patients with mood and anxiety disorders: physiopathological basis. Neurol Sci (2010) 31(Suppl 1):S99–101.10.1007/s10072-010-0296-3
281
LouterMAWardenaarKJVeenGvan OosterhoutWPZitmanFGFerrariMDet alAllodynia is associated with a higher prevalence of depression in migraine patients. Cephalalgia (2014) 34(14):1187–92.10.1177/0333102414532554
282
ParkSPSeoJGLeeWK. Osmophobia and allodynia are critical factors for suicidality in patients with migraine. J Headache Pain (2015) 16:529.10.1186/s10194-015-0529-1
283
Zambito MarsalaSPistacchiMToccoPGioulisMFabrisFBrigoFet alPain perception in major depressive disorder: a neurophysiological case-control study. J Neurol Sci (2015) 357(1–2):19–21.10.1016/j.jns.2015.06.051
284
MonroeSMHarknessKL. Life stress, the “kindling” hypothesis, and the recurrence of depression: considerations from a life stress perspective. Psychol Rev (2005) 112(2):417–45.10.1037/0033-295X.112.2.417
285
BigalMELiptonRB. Modifiable risk factors for migraine progression (or for chronic daily headaches) – clinical lessons. Headache (2006) 46(Suppl 3):S144–6.10.1111/j.1526-4610.2006.00566.x
286
KempAHSilbersteinRBArmstrongSMNathanPJ. Gender differences in the cortical electrophysiological processing of visual emotional stimuli. Neuroimage (2004) 21(2):632–46.10.1016/j.neuroimage.2003.09.055
287
RivatCBeckerCBlugeotAZeauBMauborgneAPohlMet alChronic stress induces transient spinal neuroinflammation, triggering sensory hypersensitivity and long-lasting anxiety-induced hyperalgesia. Pain (2010) 150(2):358–68.10.1016/j.pain.2010.05.031
288
Berthold-LoslebenMHimmerichH. The TNF-alpha system: functional aspects in depression, narcolepsy and psychopharmacology. Curr Neuropharmacol (2008) 6(3):193–202.10.2174/157015908785777238
289
PeresMFSanchez del RioMSeabraMLTufikSAbuchamJCipolla-NetoJet alHypothalamic involvement in chronic migraine. J Neurol Neurosurg Psychiatry (2001) 71(6):747–51.10.1136/jnnp.71.6.747
290
SolomonMBHermanJP. Sex differences in psychopathology: of gonads, adrenals and mental illness. Physiol Behav (2009) 97(2):250–8.10.1016/j.physbeh.2009.02.033
291
OxenkrugGF. Tryptophan kynurenine metabolism as a common mediator of genetic and environmental impacts in major depressive disorder: the serotonin hypothesis revisited 40 years later. Isr J Psychiatry Relat Sci (2010) 47(1):56–63.
292
GundlahCAlvesSEClarkJAPaiLYSchaefferJMRohrerSP. Estrogen receptor-beta regulates tryptophan hydroxylase-1 expression in the murine midbrain raphe. Biol Psychiatry (2005) 57(8):938–42.10.1016/j.biopsych.2005.01.014
293
RosenblatJDChaDSMansurRBMcIntyreRS. Inflamed moods: a review of the interactions between inflammation and mood disorders. Prog Neuropsychopharmacol Biol Psychiatry (2014) 53:23–34.10.1016/j.pnpbp.2014.01.013
294
CizzaGMarquesAHEskandariFChristieICTorvikSSilvermanMNet alElevated neuroimmune biomarkers in sweat patches and plasma of premenopausal women with major depressive disorder in remission: the POWER study. Biol Psychiatry (2008) 64(10):907–11.10.1016/j.biopsych.2008.05.035
295
CremaLSchlabitzMTagliariBCunhaASimaoFKrolowRet alNa+, K+ ATPase activity is reduced in amygdala of rats with chronic stress-induced anxiety-like behavior. Neurochem Res (2010) 35(11):1787–95.10.1007/s11064-010-0245-9
296
KirshenbaumGSClapcoteSJDuffySBurgessCRPetersenJJarowekKJet alMania-like behavior induced by genetic dysfunction of the neuron-specific Na+,K+-ATPase alpha3 sodium pump. Proc Natl Acad Sci U S A (2011) 108(44):18144–9.10.1073/pnas.1108416108
297
KirshenbaumGSSaltzmanKRoseBPetersenJVilsenBRoderJC. Decreased neuronal Na+,K+-ATPase activity in Atp1a3 heterozygous mice increases susceptibility to depression-like endophenotypes by chronic variable stress. Genes Brain Behav (2011) 10(5):542–50.10.1111/j.1601-183X.2011.00691.x
298
WangFCaiBLiKCHuXYLuYJWangQet alFXYD2, a gamma subunit of Na(+), K(+)-ATPase, maintains persistent mechanical allodynia induced by inflammation. Cell Res (2015) 25(3):318–34.10.1038/cr.2015.12
Summary
Keywords
angiotensin, asthma, blood–brain barrier, estrogen, mast cells, progesterone, sodium–potassium ATPase, testosterone
Citation
Loewendorf AI, Matynia A, Saribekyan H, Gross N, Csete M and Harrington M (2016) Roads Less Traveled: Sexual Dimorphism and Mast Cell Contributions to Migraine Pathology. Front. Immunol. 7:140. doi: 10.3389/fimmu.2016.00140
Received
30 September 2015
Accepted
31 March 2016
Published
19 April 2016
Volume
7 - 2016
Edited by
Xin M. Luo, Virginia Tech, USA
Reviewed by
Marcelo M. Valença, Federal University of Pernambuco, Brazil; Natalio Garbi, University of Bonn, Germany
Updates
Copyright
© 2016 Loewendorf, Matynia, Saribekyan, Gross, Csete and Harrington.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Andrea I. Loewendorf, loewendorf@hmri.org
Specialty section: This article was submitted to Immunological Tolerance, a section of the journal Frontiers in Immunology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.